0001014739-25-000022.txt : 20250429 0001014739-25-000022.hdr.sgml : 20250429 20250429160041 ACCESSION NUMBER: 0001014739-25-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Option Care Health, Inc. CENTRAL INDEX KEY: 0001014739 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 050489664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11993 FILM NUMBER: 25886941 BUSINESS ADDRESS: STREET 1: 3000 LAKESIDE DR STREET 2: SUITE 300N CITY: BANNOCKBURN STATE: IL ZIP: 60015 BUSINESS PHONE: 312 940 2443 MAIL ADDRESS: STREET 1: 3000 LAKESIDE DR STREET 2: SUITE 300N CITY: BANNOCKBURN STATE: IL ZIP: 60015 FORMER COMPANY: FORMER CONFORMED NAME: BioScrip, Inc. DATE OF NAME CHANGE: 20050314 FORMER COMPANY: FORMER CONFORMED NAME: MIM CORP DATE OF NAME CHANGE: 19960516 10-Q 1 bios-20250331.htm 10-Q bios-20250331
000101473912/312025Q1FALSExbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbios:pharmacybios:suitebios:segmentxbrli:pure00010147392025-01-012025-03-3100010147392025-04-2500010147392025-03-3100010147392024-12-3100010147392024-01-012024-03-3100010147392023-12-3100010147392024-03-310001014739us-gaap:PreferredStockMember2023-12-310001014739us-gaap:CommonStockMember2023-12-310001014739us-gaap:TreasuryStockCommonMember2023-12-310001014739us-gaap:AdditionalPaidInCapitalMember2023-12-310001014739us-gaap:RetainedEarningsMember2023-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001014739us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001014739us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001014739us-gaap:RetainedEarningsMember2024-01-012024-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001014739us-gaap:PreferredStockMember2024-03-310001014739us-gaap:CommonStockMember2024-03-310001014739us-gaap:TreasuryStockCommonMember2024-03-310001014739us-gaap:AdditionalPaidInCapitalMember2024-03-310001014739us-gaap:RetainedEarningsMember2024-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001014739us-gaap:PreferredStockMember2024-12-310001014739us-gaap:CommonStockMember2024-12-310001014739us-gaap:TreasuryStockCommonMember2024-12-310001014739us-gaap:AdditionalPaidInCapitalMember2024-12-310001014739us-gaap:RetainedEarningsMember2024-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001014739us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001014739us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001014739us-gaap:RetainedEarningsMember2025-01-012025-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001014739us-gaap:PreferredStockMember2025-03-310001014739us-gaap:CommonStockMember2025-03-310001014739us-gaap:TreasuryStockCommonMember2025-03-310001014739us-gaap:AdditionalPaidInCapitalMember2025-03-310001014739us-gaap:RetainedEarningsMember2025-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001014739bios:LegacyHealthSystemsMember2025-03-310001014739us-gaap:CorporateJointVentureMember2024-01-012024-03-310001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-03-310001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-03-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-03-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-03-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberbios:AccountsReceivableBenchmarkMember2025-01-012025-03-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberbios:AccountsReceivableBenchmarkMember2024-01-012024-12-310001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2025-01-012025-03-310001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2024-01-012024-03-310001014739bios:IntramedPlusIncMember2025-01-240001014739bios:IntramedPlusIncMember2025-01-242025-01-240001014739bios:IntramedPlusIncMemberbios:ReferralSourcesMember2025-01-240001014739bios:IntramedPlusIncMemberus-gaap:TrademarksAndTradeNamesMember2025-01-240001014739bios:IntramedPlusIncMemberbios:ReferralSourcesMember2025-01-242025-01-240001014739bios:IntramedPlusIncMemberus-gaap:TrademarksAndTradeNamesMember2025-01-242025-01-240001014739bios:CommercialCustomerMember2025-01-012025-03-310001014739bios:CommercialCustomerMember2024-01-012024-03-310001014739bios:GovernmentCustomerMember2025-01-012025-03-310001014739bios:GovernmentCustomerMember2024-01-012024-03-310001014739bios:PatientCustomerMember2025-01-012025-03-310001014739bios:PatientCustomerMember2024-01-012024-03-310001014739us-gaap:StateAndLocalJurisdictionMember2024-01-012024-03-310001014739us-gaap:StateAndLocalJurisdictionMember2025-03-310001014739us-gaap:StockOptionMember2025-01-012025-03-310001014739us-gaap:StockOptionMember2024-01-012024-03-310001014739bios:RestrictedStockAwardMember2025-01-012025-03-310001014739bios:RestrictedStockAwardMember2024-01-012024-03-310001014739bios:PerformanceStockUnitMember2025-01-012025-03-310001014739bios:PerformanceStockUnitMember2024-01-012024-03-310001014739bios:InfusionPumpsMember2025-03-310001014739bios:InfusionPumpsMember2024-12-310001014739bios:EquipmentFurnitureAndOtherMember2025-03-310001014739bios:EquipmentFurnitureAndOtherMember2024-12-310001014739us-gaap:LeaseholdImprovementsMember2025-03-310001014739us-gaap:LeaseholdImprovementsMember2024-12-310001014739us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2025-03-310001014739us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-12-310001014739us-gaap:AssetUnderConstructionMember2025-03-310001014739us-gaap:AssetUnderConstructionMember2024-12-310001014739us-gaap:CostOfSalesMember2025-01-012025-03-310001014739us-gaap:CostOfSalesMember2024-01-012024-03-310001014739us-gaap:OperatingExpenseMember2025-01-012025-03-310001014739us-gaap:OperatingExpenseMember2024-01-012024-03-310001014739us-gaap:CustomerListsMember2025-03-310001014739us-gaap:CustomerListsMember2024-12-310001014739us-gaap:TrademarksAndTradeNamesMember2025-03-310001014739us-gaap:TrademarksAndTradeNamesMember2024-12-310001014739us-gaap:OtherIntangibleAssetsMember2025-03-310001014739us-gaap:OtherIntangibleAssetsMember2024-12-310001014739us-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2025-03-310001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2025-03-310001014739bios:SecondLienTermLoanMemberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2024-12-310001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-12-310001014739bios:SecondLienTermLoanMemberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:SeniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:SeniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:SeniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2025-01-012025-03-310001014739us-gaap:SeniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2024-01-012024-03-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2024-01-012024-03-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2025-01-012025-03-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2025-03-310001014739bios:FirstLienCreditAgreementSecondAmendmentMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:FairValueInputsLevel1Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:FairValueInputsLevel2Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:FairValueInputsLevel3Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:SeniorNotesMember2025-03-310001014739us-gaap:FairValueInputsLevel1Memberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:FairValueInputsLevel3Memberus-gaap:SeniorNotesMember2025-03-310001014739us-gaap:FairValueInputsLevel1Member2025-03-310001014739us-gaap:FairValueInputsLevel2Member2025-03-310001014739us-gaap:FairValueInputsLevel3Member2025-03-310001014739bios:FirstLienTermLoanMemberus-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-10-310001014739bios:FirstLienTermLoanMemberus-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-10-012021-10-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2025-03-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2025-03-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-12-310001014739us-gaap:InterestRateCapMember2025-01-012025-03-310001014739us-gaap:InterestRateCapMember2024-01-012024-03-310001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2025-01-012025-03-310001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2024-01-012024-03-310001014739bios:A2018PlanMember2021-05-310001014739bios:A2018PlanMember2024-05-012024-05-3100010147392024-05-310001014739bios:HCIIncentiveUnitsMemberbios:A2018PlanMember2025-01-012025-03-310001014739bios:HCIIncentiveUnitsMemberbios:A2018PlanMember2024-01-012024-03-310001014739us-gaap:CommonStockMember2023-12-060001014739us-gaap:CommonStockMember2025-01-012025-03-310001014739us-gaap:CommonStockMember2024-01-012024-03-310001014739us-gaap:CorporateJointVentureMember2025-01-012025-03-310001014739us-gaap:CorporateJointVentureMember2025-03-310001014739us-gaap:CorporateJointVentureMember2024-12-310001014739bios:ReportableSegmentMember2025-01-012025-03-310001014739bios:ReportableSegmentMember2024-01-012024-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2025
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from     to             
Commission file number: 001-11993
OPCH_Logo.jpg
OPTION CARE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware05-0489664
(State of incorporation)(I.R.S. Employer Identification No.)
3000 Lakeside Dr.Suite 300N, Bannockburn, IL60015
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
312-940-2443
Securities registered pursuant to Section 12(b) of the Act:
Title of each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareOPCHNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑     No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☑     Accelerated filer ☐     Non-accelerated filer ☐      Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐     No ☑  

On April 25, 2025, there were 163,747,250 shares of the registrant’s Common Stock outstanding.
1


TABLE OF CONTENTS
2

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to "Option Care Health," the “Company,” “we,” “us” and “our” refer to Option Care Health, Inc. and its consolidated subsidiaries.
Forward-Looking Statements
This Form 10-Q includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning our expectations regarding industry and macroeconomic trends and our operating performance. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. If any of these risks materialize, or if any of our assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2024 (our “Form 10-K”) filed with the U.S. Securities and Exchange Commission (the “SEC”). Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this Form 10-Q. Any forward-looking statement made by us in this Form 10-Q speaks only as of the date hereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
3
PART I
FINANCIAL INFORMATION
Item 1.     Financial Statements
4
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)
March 31, 2025December 31, 2024
(unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$171,372 $412,565 
Accounts receivable, net476,649 409,733 
Inventories369,034 388,131 
Prepaid expenses and other current assets82,320 112,198 
Total current assets1,099,375 1,322,627 
 
NONCURRENT ASSETS:
Property and equipment, net131,264 127,367 
Operating lease right-of-use asset90,950 86,528 
Intangible assets, net24,427 16,993 
Referral sources, net312,586 284,017 
Goodwill1,605,930 1,540,246 
Other noncurrent assets43,981 43,965 
Total noncurrent assets2,209,138 2,099,116 
TOTAL ASSETS $3,308,513 $3,421,743 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
CURRENT LIABILITIES:  
Accounts payable$528,848 $610,779 
Accrued compensation and employee benefits49,664 63,028 
Accrued expenses and other current liabilities106,177 77,783 
Current portion of operating lease liability22,463 22,044 
Current portion of long-term debt6,512 6,512 
Total current liabilities713,664 780,146 
 
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion1,104,160 1,104,641 
Operating lease liability, net of current portion89,825 84,776 
Deferred income taxes48,946 47,576 
Other noncurrent liabilities1,084 366 
Total noncurrent liabilities1,244,015 1,237,359 
Total liabilities1,957,679 2,017,505 
 
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March 31, 2025 and December 31, 2024
— — 
Common stock; $0.0001 par value: 250,000,000 shares authorized, 184,376,321 shares issued and 163,744,493 shares outstanding as of March 31, 2025; 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024
18 18 
Treasury stock; 20,631,828 and 17,585,613 shares outstanding, at cost, as of March 31, 2025 and December 31, 2024, respectively
(608,711)(507,598)
Paid-in capital1,234,800 1,231,435 
Retained earnings716,078 669,336 
Accumulated other comprehensive income8,649 11,047 
Total stockholders’ equity1,350,834 1,404,238 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$3,308,513 $3,421,743 
The accompanying notes to unaudited condensed consolidated financial statements are an integral part of these statements.
5
OPTION CARE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
Three Months Ended March 31,
 20252024
NET REVENUE$1,332,972 $1,146,052 
COST OF REVENUE1,069,920 907,552 
GROSS PROFIT263,052 238,500 
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses168,118 154,742 
Depreciation and amortization expense15,746 14,728 
Total operating expenses183,864 169,470 
OPERATING INCOME79,188 69,030 
 
OTHER INCOME (EXPENSE):
Interest expense, net(13,231)(13,202)
Equity in earnings of joint ventures1,729 1,125 
Other, net(4,130)2 
Total other expense(15,632)(12,075)
 
INCOME BEFORE INCOME TAXES63,556 56,955 
INCOME TAX EXPENSE16,814 12,164 
NET INCOME$46,742 $44,791 
 
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $783 and $(454), respectively
$(2,398)$1,551 
OTHER COMPREHENSIVE (LOSS) INCOME(2,398)1,551 
NET COMPREHENSIVE INCOME $44,344 $46,342 
 
EARNINGS PER COMMON SHARE:
Earnings per share, basic$0.28 $0.26 
Earnings per share, diluted$0.28 $0.26 
 
Weighted average common shares outstanding, basic165,460 173,928 
Weighted average common shares outstanding, diluted166,804 175,624 
The accompanying notes to unaudited condensed consolidated financial statements are an integral part of these statements.
6
OPTION CARE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
Three Months Ended March 31,
 20252024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income$46,742 $44,791 
Adjustments to reconcile net income to net cash used in operations:
Depreciation and amortization expense16,373 15,305 
Non-cash operating lease costs9,002 7,663 
Deferred income taxes - net1,370 2,964 
Amortization of deferred financing costs1,147 1,132 
Equity in earnings of joint ventures(1,729)(1,125)
Stock-based incentive compensation expense8,801 9,605 
Distribution from equity method investments— 750 
Other adjustments(949)108 
Changes in operating assets and liabilities:
Accounts receivable, net(56,788)(195,992)
Inventories21,790 32,056 
Prepaid expenses and other current assets28,444 4,878 
Accounts payable(88,101)59,223 
Accrued compensation and employee benefits(14,458)(49,884)
Accrued expenses and other current liabilities27,503 6,811 
Operating lease liabilities(7,956)(6,651)
Other noncurrent assets and liabilities1,595 (418)
Net cash used in operating activities(7,214)(68,784)
 
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment(9,371)(5,820)
Business acquisitions, net of cash acquired(117,322)— 
Net cash used in investing activities(126,693)(5,820)
 
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock-based compensation tax withholdings(7,385)(8,182)
Purchase of company stock, and related excise taxes(100,222)(40,050)
Repayments of debt principal(1,628)(1,500)
Other financing activities1,949 — 
Net cash used in financing activities(107,286)(49,732)
NET DECREASE IN CASH AND CASH EQUIVALENTS(241,193)(124,336)
Cash and cash equivalents - beginning of the period412,565 343,849 
CASH AND CASH EQUIVALENTS - END OF PERIOD$171,372 $219,513 
 
Supplemental disclosure of cash flow information:
Cash paid for interest$10,763 $12,173 
Cash paid for income taxes$833 $2 
Cash paid for operating leases$7,548 $7,085 
The accompanying notes to unaudited condensed consolidated financial statements are an integral part of these statements.
7
OPTION CARE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(IN THOUSANDS)
Preferred StockCommon StockTreasury StockPaid-in CapitalRetained Earnings Accumulated Other Comprehensive Income (Loss)Total Stockholders’ Equity
Balance - December 31, 2023$— $18 $(255,107)$1,204,270 $457,513 $14,978 $1,421,672 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (8,182)— — (8,182)
Stock-based incentive compensation— — — 9,605 — — 9,605 
Purchase of company stock, and related tax effects— — (40,289)— — — (40,289)
Net income— — — — 44,791 — 44,791 
Other comprehensive income— — — — — 1,551 1,551 
Balance - March 31, 2024$— $18 $(295,396)$1,205,693 $502,304 $16,529 $1,429,148 
 
Balance - December 31, 2024$— $18 $(507,598)$1,231,435 $669,336 $11,047 $1,404,238 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (5,436)— — (5,436)
Stock-based incentive compensation— — — 8,801 — — 8,801 
Purchase of company stock, and related tax effects— — (101,113)— — — (101,113)
Net income— — — — 46,742 — 46,742 
Other comprehensive loss— — — — — (2,398)(2,398)
Balance - March 31, 2025$— $18 $(608,711)$1,234,800 $716,078 $8,649 $1,350,834 
The accompanying notes to unaudited condensed consolidated financial statements are an integral part of these statements.
8
OPTION CARE HEALTH, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
Corporate Organization and Business — Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 91 full service pharmacies, including 77 with ambulatory infusion suites. Additionally, the Company has 99 stand-alone ambulatory infusion suites, including 16 with advanced practitioner capabilities. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company’s stock is listed on the Nasdaq Global Select Market as of March 31, 2025.
Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2024 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.
Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.
9
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2025, cash equivalents consisted of money market funds.
Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $33.9 million and $54.4 million as of March 31, 2025 and December 31, 2024, respectively.
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2025 and December 31, 2024, the balance of the investments was $26.2 million and $24.5 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.7 million and $1.1 million for the three months ended March 31, 2025 and 2024, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million. See Note 16, Related-Party Transactions, for discussion of related-party transactions with these investees.
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% and 14% for the three months ended March 31, 2025 and 2024, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.
For the three months ended March 31, 2025 and 2024, approximately 12% of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of March 31, 2025 and December 31, 2024, approximately 11% of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the three months ended March 31, 2025 and 2024, approximately 66% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results.
10
3. BUSINESS COMBINATIONS
Intramed Plus, Inc. — On January 24, 2025, pursuant to the securities purchase agreement dated November 27, 2024, the Company completed the acquisition of 100% of the equity interests in Intramed Plus, Inc. (“Intramed Plus”) for a purchase price, net of cash acquired, of $117.3 million.
The allocation of the purchase price of Intramed Plus was accounted for as a business combination in accordance with ASC Topic 805, Business Combinations, with the total purchase price being allocated to the assets and liabilities acquired based on the relative fair value of each asset and liability. The following is a preliminary estimate of the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2025, which remains open for accounts receivable, accounts payable and intangible assets (in thousands):
Amount
Accounts receivable, net$10,128 
Referral sources (1)36,800 
Trademarks/names (1)8,300 
Inventory2,693 
Other assets4,831 
Accounts payable and other liabilities(11,114)
Fair value identifiable assets and liabilities51,638 
Goodwill (2)65,684 
Cash acquired2,968 
Purchase price120,290 
Less: cash acquired (2,968)
Purchase price, net of cash acquired$117,322 
(1) Referral sources and trademarks/names have been assigned a useful life of 15 years.
(2) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.
11
4. REVENUE
The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2025 and 2024 (in thousands):
Three Months Ended March 31,
20252024
Commercial payers$1,144,932 $988,043 
Government payers160,518 138,310 
Patients27,522 19,699 
Net revenue$1,332,972 $1,146,052 
5. INCOME TAXES
During the three months ended March 31, 2025 and 2024, the Company recorded tax expense of $16.8 million and $12.2 million, respectively, which represents an effective tax rate of 26.5% and 21.4%, respectively. The variance in the Company’s effective tax rate of 26.5% for the three months ended March 31, 2025, compared to the federal statutory rate of 21.0%, is primarily attributable to the difference between federal and state tax rates, and various non-deductible expenses. The variance in the Company’s effective tax rate of 21.4% for the three months ended March 31, 2024, compared to the federal statutory rate of 21.0%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the three months ended March 31, 2024, the Company released $2.2 million of state valuation allowance.
The Company maintains a valuation allowance of $3.3 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.
The Company’s tax expense of $16.8 million and $12.2 million for the three months ended March 31, 2025 and 2024, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.
The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (“Code”) Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses.
12
6. EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March 31, 2025 and 2024 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Three Months Ended March 31,
20252024
Stock option awards702,287 880,815 
Restricted stock awards604,589 279,144 
Performance stock unit awards171,854 149,561 
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended March 31,
20252024
Numerator:
Net income$46,742 $44,791 
Denominator:
Weighted average number of common shares outstanding165,460 173,928 
Earnings per common share:
Earnings per common share, basic$0.28 $0.26 
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended March 31,
 20252024
Numerator:
Net income$46,742 $44,791 
Denominator:
Weighted average number of common shares outstanding165,460 173,928 
Effect of dilutive securities1,344 1,696 
Weighted average number of common shares outstanding, diluted166,804 175,624 
Earnings per common share:
Earnings per common share, diluted$0.28 $0.26 
13
7. LEASES
During the three months ended March 31, 2025 and 2024, the Company incurred operating lease expenses of $8.2 million and $7.9 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2025 and December 31, 2024, the weighted-average remaining lease term was 6.6 years and 6.5 years, respectively, and the weighted-average discount rate was 6.77% and 6.56%, respectively.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$21,946 
202627,537 
202722,446 
202815,840 
202911,233 
Thereafter43,576 
Total lease payments142,578 
Less: interest(30,290)
Present value of lease liabilities$112,288 
During the three months ended March 31, 2025 and 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flows of $10.8 million and $11.3 million, respectively, related to increases in the operating lease right-of-use assets and operating lease liabilities. As of March 31, 2025, the Company did not have any significant operating or financing leases that had not yet commenced.
8. PROPERTY AND EQUIPMENT
Property and equipment was as follows as of March 31, 2025 and December 31, 2024 (in thousands):
March 31, 2025December 31, 2024
Infusion pumps$38,623 $37,659 
Equipment, furniture and other21,222 24,055 
Leasehold improvements117,828 116,675 
Computer software, purchased and internally developed48,365 46,532 
Assets under development25,376 22,990 
251,414 247,911 
Less: accumulated depreciation(120,150)(120,544)
Property and equipment, net$131,264 $127,367 
Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2025 and 2024 (in thousands):
Three Months Ended March 31,
20252024
Depreciation expense in cost of revenue$627 $576 
Depreciation expense in operating expenses6,649 6,120 
Total depreciation expense$7,276 $6,696 
14
9. GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill consist of the following for the three months ended March 31, 2025 (in thousands):
Amount
Balance at December 31, 2024$1,540,246 
Acquisitions65,684 
Balance at March 31, 2025$1,605,930 
The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2025 and December 31, 2024 (in thousands):
March 31, 2025December 31, 2024
Gross intangible assets:
Referral sources$551,188 $514,388 
Trademarks/names47,436 39,136 
Other amortizable intangible assets985 985 
Total gross intangible assets599,609 554,509 
Accumulated amortization:
Referral sources(238,602)(230,371)
Trademarks/names(23,416)(22,599)
Other amortizable intangible assets(578)(529)
Total accumulated amortization(262,596)(253,499)
Total intangible assets, net$337,013 $301,010 
Amortization expense for intangible assets was $9.1 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively.
15
10. INDEBTEDNESS
Long-term debt consisted of the following as of March 31, 2025 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan629,988 (5,194)(7,087)617,707 
Senior Notes500,000 — (7,035)492,965 
$1,129,988 $(5,194)$(14,122)1,110,672 
Less: current portion(6,512)
Total long-term debt$1,104,160 
Long-term debt consisted of the following as of December 31, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan631,617 (5,537)(7,555)618,525 
Senior Notes500,000 — (7,372)492,628 
$1,131,617 $(5,537)$(14,927)1,111,153 
Less: current portion(6,512)
Total long-term debt$1,104,641 
The interest rate on the First Lien Term Loan was 6.57% and 6.82% as of March 31, 2025 and December 31, 2024, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 6.58% and 8.20% for the three months ended March 31, 2025 and 2024, respectively. The First Lien Term Loan matures on October 27, 2028.
The interest rate on the Senior Notes was 4.375% as of March 31, 2025 and December 31, 2024. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three months ended March 31, 2025 and 2024. The Senior Notes mature on October 31, 2029.
As of March 31, 2025, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans.
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$4,884 
20266,512 
20276,512 
2028612,080 
2029500,000 
Total$1,129,988 
During the three months ended March 31, 2025 and 2024, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 11, Derivative Instruments, for further discussion.
The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2025 (in thousands):
Financial Instrument
Carrying Value as of March 31, 2025
Markets for Identical Item (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan$617,707 $— $631,563 $— 
Senior Notes492,965 — 463,750 — 
Total debt instruments$1,110,672 $— $1,095,313 $— 
See Note 12, Fair Value Measurements, for further discussion.
16
11. DERIVATIVE INSTRUMENTS
The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.
In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a five-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.
The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionMarch 31, 2025December 31, 2024
Interest rate cap designated as cash flow hedgePrepaid expenses and other current assets$7,515 $8,034 
Interest rate cap designated as cash flow hedgeOther noncurrent assets4,018 6,680 
Total derivative assets$11,533 $14,714 
The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the hedging instrument is recognized in net income through interest expense.
The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):
Three Months Ended March 31,
Derivative20252024
Interest rate cap designated as cash flow hedge$(3,181)$2,005 
The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):
Three Months Ended March 31,
DerivativeIncome Statement Caption20252024
Interest rate cap designated as cash flow hedgeInterest expense, net$2,191 $2,980 
17
12. FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:
•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).
There were no other material assets or liabilities measured at fair value at March 31, 2025 and December 31, 2024.
13. COMMITMENTS AND CONTINGENCIES
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.
The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.
However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
18
14. STOCK-BASED INCENTIVE COMPENSATION
Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by stockholders on May 3, 2018 and amended and restated on May 19, 2021 and May 15, 2024, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. As of May 2021, a total of 9,101,734 shares of common stock were authorized for issuance under the 2018 Plan. In May 2024, an additional 4,000,000 shares were authorized for issuance under the 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March 31, 2025 and 2024. During the three months ended March 31, 2025 and 2024, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $8.8 million and $9.6 million, respectively.
15. STOCKHOLDERS’ EQUITY
Warrants — As of March 31, 2025 and December 31, 2024, the Company has warrants outstanding which entitle holders to purchase an immaterial number of shares of common stock.
Share Repurchase Program — The Company’s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.
During the three months ended March 31, 2025 and 2024, the Company purchased 3,046,215 and 1,251,739 shares of common stock for an average share price of $32.83 and $31.96, totaling $100.0 million and $40.0 million, respectively. All repurchased shares became treasury stock. As of March 31, 2025, the Company is authorized to repurchase up to a remaining $400.0 million of common stock of the Company.
Shares Outstanding — The following table shows the Company’s changes in shares of common stock for the three months ended March 31, 2025 and 2024 (in thousands):
20252024
Balance, beginning of the year166,261 174,576 
Equity award issuances529 492 
Share repurchases(3,046)(1,252)
Balance March 31,163,744 173,816 
16. RELATED-PARTY TRANSACTIONS
Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.8 million and $1.5 million for the three months ended March 31, 2025 and 2024, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million.
The Company had amounts due to its joint ventures of $2.5 million and $1.4 million as of March 31, 2025 and December 31, 2024, respectively. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.
19
17. SEGMENT REPORTING
The Company has adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures and has revised prior year disclosures to conform with the current year presentation. The Company operates as a single reportable segment, infusion services. Infusion services derives revenue through the clinical management of infusion therapy, nursing support and care coordination in order to provide solutions to complex patient conditions in the home or other nonhospital settings. The Company’s infusion services segment activities are managed on a consolidated basis and therapies are distributed and administered in a similar manner.
Operating segments have been identified based on the financial information utilized by the Company’s Chief Executive Officer, the chief operating decision maker (“CODM”). The CODM uses net income as a measure of profitability to assess segment performance and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.
The following table reflects results of operations of the Company’s reportable segment (in thousands):
Three Months Ended March 31,
20252024
Infusion services net revenue$1,311,181 $1,125,662 
Other revenue (1)21,791 20,390 
Total Option Care Health revenue1,332,972 1,146,052 
(Expense) Income:
Cost of net revenues - drugs(933,068)(777,260)
Salaries, benefits, and other employee expense(205,692)(191,815)
Other segment items (2)(99,278)(93,219)
Depreciation and amortization expense(15,746)(14,728)
Interest expense, net(13,231)(13,202)
Equity in earnings of joint ventures1,729 1,125 
Other, net(4,130)2 
Income tax expense(16,814)(12,164)
Net Income$46,742 $44,791 
(1) Represents business activities related to other miscellaneous revenue streams.
(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.
20
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Unless the context requires otherwise, references in this report to "Option Care Health," the “Company,” “we,” “us” and “our” refer to Option Care Health, Inc. and its consolidated subsidiaries. Management’s discussion and analysis of financial condition and results of operations (“MD&A”) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial condition. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and the related notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q (this “Form 10-Q”). Certain statements in this Item 2 of Part I of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2024 (our “Form 10-K”), may cause our actual results, financial position, and cash and cash equivalents generated from operations to differ materially from these forward-looking statements.
Business Overview
Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 190 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Our services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, and dietitians work with the physician to develop a plan of care suited to each patient’s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, therapies for neurological disorders and chronic inflammatory disorders, immunoglobulin therapy, and other therapies for chronic and acute conditions. The Company operates in one reporting segment, infusion services.
21
Composition of Results of Operations
The following results of operations include the accounts of Option Care Health and our subsidiaries for the three months ended March 31, 2025 and 2024.
Gross Profit
Gross profit represents our net revenue less cost of revenue.
Net Revenue. Infusion and related healthcare services revenue is reported at the estimated net realizable amounts from third-party payers and patients for goods sold and services rendered. When pharmaceuticals are provided to a patient, revenue is recognized upon delivery of the goods. When nursing services are provided, revenue is recognized when the services are rendered.
Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded.
Cost of Revenue. Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients. In addition to product costs, cost of revenue includes warehousing costs, purchasing costs, depreciation expense relating to revenue-generating assets, such as infusion pumps, shipping and handling costs, and wages and related costs for the pharmacists, nurses, and all other employees and contracted workers directly involved in providing service to the patient.
The Company receives volume-based rebates and prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These payments are recorded as a reduction of inventory and are accounted for as a reduction of cost of revenue when the related inventory is sold.
Operating Costs and Expenses
Selling, General and Administrative Expenses. Selling, general and administrative expenses consist principally of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.
Depreciation and Amortization Expense. Depreciation within this caption relates to property and equipment and amortization relates to intangibles. Depreciation of revenue-generating assets, such as infusion pumps, is included in cost of revenue.
Other Income (Expense)
Interest Expense, Net. Interest expense consists principally of interest payments on the Company’s outstanding borrowings under the First Lien Term Loan, Revolver Facility, Senior Notes, amortization of discount and deferred financing fees, payments associated with the interest rate cap, and interest income earned on cash and cash equivalents. Refer to the “Liquidity and Capital Resources” section below for further discussion of these outstanding borrowings.
Equity in Earnings of Joint Ventures. Equity in earnings of joint ventures consists of our proportionate share of equity earnings or losses from equity investments in two infusion joint ventures with healthcare systems.
Other, Net. Other income (expense) primarily includes activity related to non-operating income and expenses.
Income Tax Expense. The Company is subject to taxation in the United States and various states. The Company’s income tax expense is reflective of the current federal and state tax rates.
Change in Unrealized (Loss) Gain on Cash Flow Hedge, Net of Income Tax Benefit (Expense). Change in unrealized (loss) gain on cash flow hedge, net of income tax benefit (expense), consists of the (loss) gain associated with the changes in the fair value of derivatives designated as hedging instruments related to the interest rate cap hedge, net of income taxes.
22
Results of Operations
The following table presents Option Care Health’s consolidated results of operations for the three months ended March 31, 2025 and 2024 (in thousands, except for percentages):
Three Months Ended March 31,
 20252024
Amount% of RevenueAmount% of Revenue
NET REVENUE$1,332,972 100.0 %$1,146,052 100.0 %
COST OF REVENUE1,069,920 80.3 %907,552 79.2 %
GROSS PROFIT263,052 19.7 %238,500 20.8 %
 
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses168,118 12.6 %154,742 13.5 %
Depreciation and amortization expense15,746 1.2 %14,728 1.3 %
Total operating expenses183,864 13.8 %169,470 14.8 %
OPERATING INCOME79,188 5.9 %69,030 6.0 %
 
OTHER INCOME (EXPENSE):
Interest expense, net(13,231)(1.0)%(13,202)(1.2)%
Equity in earnings of joint ventures1,729 0.1 %1,125 0.1 %
Other, net(4,130)(0.3)%2 — %
Total other expense(15,632)(1.2)%(12,075)(1.1)%
 
INCOME BEFORE INCOME TAXES63,556 4.8 %56,955 5.0 %
INCOME TAX EXPENSE16,814 1.3 %12,164 1.1 %
NET INCOME$46,742 3.5 %$44,791 3.9 %
 
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $783 and ($454), respectively(2,398)(0.2)%1,551 0.1 %
OTHER COMPREHENSIVE (LOSS) INCOME(2,398)(0.2)%1,551 0.1 %
NET COMPREHENSIVE INCOME $44,344 3.3 %$46,342 4.0 %
23
Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024
The following tables present selected consolidated comparative results of operations from Option Care Health’s unaudited condensed consolidated financial statements for the three months ended March 31, 2025 and 2024.
Gross Profit
 Three Months Ended March 31,
20252024Variance
(in thousands, except for percentages)
Net revenue$1,332,972 $1,146,052 $186,920 16.3 %
Cost of revenue1,069,920 907,552 162,368 17.9 %
Gross profit$263,052 $238,500 $24,552 10.3 %
Gross profit margin19.7 %20.8 %
The increase in net revenue was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that grew in the mid-teens relative to the prior year while chronic revenue grew in the high-teens. Acute growth was largely driven by the impact of shifts in the competitive landscape, which increased the volume of patient service. The increase in cost of revenue was primarily driven by the growth in revenue and therapy mix. The decrease in gross profit margin was primarily due to certain higher cost therapies included within chronic growth (including rare and orphan therapies). Additionally, the company executed on several initiatives to temporarily mitigate the impact of the previously disclosed reduction in procurement spread in the first quarter. The Company expects the full negative impact to gross profit to materialize in the second quarter through the remainder of the year.
Operating Expenses
 Three Months Ended March 31,
 20252024Variance
(in thousands, except for percentages)
Selling, general and administrative expenses$168,118 $154,742 $13,376 8.6 %
Depreciation and amortization expense15,746 14,728 1,018 6.9 %
Total operating expenses$183,864 $169,470 $14,394 8.5 %
The increase in selling, general and administrative expenses during the three months ended March 31, 2025 was primarily due to an increase in salaries, benefits, and general costs to support the business; however, these expenses have declined as a percentage of revenue to 12.6% for the three months ended March 31, 2025 compared to 13.5% for the three months ended March 31, 2024, due to the Company’s focus on leveraging existing infrastructure to control spending. The increase in depreciation and amortization expense was primarily due to the Intramed Plus acquisition. See Note 3, Business Combinations, of the unaudited condensed consolidated financial statements for further information.






24
Other Income (Expense)
 Three Months Ended March 31,
 20252024Variance
(in thousands, except for percentages)
Interest expense, net$(13,231)$(13,202)$(29)0.2 %
Equity in earnings of joint ventures1,729 1,125 604 53.7 %
Other, net(4,130)2 (4,132)
NM(1)
Total other expense$(15,632)$(12,075)$(3,557)29.5 %
(1) Not meaningful
The increase in Other, net is primarily attributable to accruals related to an abandoned or unclaimed property voluntary disclosure agreement program which is related to the pre-merger operations of BioScrip, Inc. (“BioScrip”), which was entered into by BioScrip prior to its merger with the Company in 2019. As of March 31, 2025, the matters related to this program are ongoing.
Income Tax Expense
 Three Months Ended March 31,
 20252024Variance
(in thousands, except for percentages)
Income tax expense$16,814 $12,164 $4,650 38.2 %
The Company recorded income tax expense of $16.8 million and $12.2 million for the three months ended March 31, 2025 and 2024, respectively, which represents an effective tax rate of 26.5% and 21.4%, respectively. The variance in the Company’s effective tax rate of 26.5% for the three months ended March 31, 2025, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, and various non-deductible expenses. The variance in the Company’s effective tax rate of 21.4% for the three months ended March 31, 2024, compared to the federal statutory rate of 21%, was also primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance.
Net Income and Other Comprehensive (Loss) Income
 Three Months Ended March 31,
 20252024Variance
(in thousands, except for percentages)
Net income$46,742 $44,791 $1,951 4.4 %
Other comprehensive (loss) income, net of tax:
Change in unrealized (loss) gain on cash flow hedges, net of income taxes(2,398)1,551 (3,949)(254.6)%
Other comprehensive (loss) income(2,398)1,551 (3,949)(254.6)%
Net comprehensive income$44,344 $46,342 $(1,998)(4.3)%
The change in net income was attributable to the factors described in the above sections.
For the three months ended March 31, 2025 and 2024, the change in unrealized (loss) gain on cash flow hedges, net of income taxes was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021.
Net comprehensive income decreased to $44.3 million for the three months ended March 31, 2025, compared to net comprehensive income of $46.3 million for the three months ended March 31, 2024, primarily as a result of the changes in the fair market value of the cash flow hedge.
25
Liquidity and Capital Resources
For the three months ended March 31, 2025 and the twelve months ended December 31, 2024, the Company’s primary sources of liquidity were cash and cash equivalents of $171.4 million and $412.6 million, respectively. As of March 31, 2025 and December 31, 2024, the Company had $395.9 million of borrowings available under its credit facilities (net of $4.1 million undrawn letters of credit issued and outstanding). During the three months ended March 31, 2025 and 2024, the Company’s cash flows from operations enabled investments in pharmacy, infusion suites, and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and share repurchases.
The Company’s primary uses of cash and cash equivalents include supporting our ongoing business activities, investment in capital expenditures in both facilities and technology, and the pursuit of acquisitions and share repurchases. Ongoing operating cash outflows are associated with procuring and dispensing drugs, personnel and other costs associated with servicing patients, as well as paying cash interest on outstanding debt and cash taxes. Ongoing investing cash flows are primarily associated with capital projects and business acquisitions, the improvement and maintenance of our pharmacy facilities and investment in our information technology systems. Ongoing financing cash flows are primarily associated with the quarterly principal payments on our outstanding debt, along with potential future share repurchases.
Our business strategy includes the deployment of capital to pursue acquisitions that complement our existing operations. We continue to evaluate acquisition opportunities and view acquisitions as a key part of our growth strategy. The Company has generally funded its acquisitions with cash and cash equivalents. The Company may require additional capital in excess of current availability in order to complete future acquisitions. It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on acceptable terms.
Short-Term and Long-Term Liquidity Requirements
The Company’s ability to make principal and interest payments on any borrowings under our credit facilities and our ability to fund planned capital expenditures will depend on our ability to generate cash and cash equivalents in the future, which to a certain extent, is subject to general economic, financial, competitive, regulatory and other conditions. Based on our current level of operations and planned capital expenditures, we believe that our existing cash and cash equivalents balances and expected cash flows generated from operations will be sufficient to meet our operating requirements over the next 12 months and beyond. We may require additional borrowings under our credit facilities and alternative forms of financings or investments to achieve our longer-term strategic plans.
Credit Facilities
The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.6 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. Interest on the First Lien Term Loan is payable monthly on either (i) the Secured Overnight Financing Rate (“SOFR”) (with a floor of 0.50% per annum) plus an applicable margin of 2.25% for Term SOFR Loans; or (ii) a base rate, plus 1.25% for Base Rate Loans.
The Senior Notes bear interest at a rate of 4.375% per annum and are payable semi-annually in arrears on October 31 and April 30 of each year. The Senior Notes mature on October 31, 2029.
The Company’s Revolver Facility provides for borrowings up to $400.0 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility will bear interest at a rate equal to, at the option of the Company, either (i) the Term SOFR applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the First Lien Credit Agreement Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent Compliance Certificate received by the Administrative Agent pursuant to the terms of the credit agreement. As of March 31, 2025, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million.
Interest payments over the course of long-term debt obligations total an estimated $249.2 million based on final maturity dates of the Company’s credit facilities. Interest payments are calculated based on current rates as of March 31, 2025. Actual payments are based on changes in SOFR and exclude the interest rate cap derivative instrument.
26
Cash Flows
Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024
The following table presents selected data from Option Care Health’s unaudited condensed consolidated statements of cash flows:
 Three Months Ended March 31,
 20252024Variance
(in thousands)
Net cash used in operating activities$(7,214)$(68,784)$61,570 
Net cash used in investing activities(126,693)(5,820)(120,873)
Net cash used in financing activities(107,286)(49,732)(57,554)
Net decrease in cash and cash equivalents(241,193)(124,336)(116,857)
Cash and cash equivalents - beginning of period412,565 343,849 68,716 
Cash and cash equivalents - end of period$171,372 $219,513 $(48,141)
Cash Flows from Operating Activities
The change in cash used in operating activities during the three months ended March 31, 2025, as compared to the cash used in operating activities in the three months ended March 31, 2024, was primarily due to the changes in accounts receivable as a result of the Change Healthcare Cybersecurity Incident that occurred in the first quarter of 2024. Additionally, cash flows from operating activities for the three months ended March 31, 2025 was impacted by the timing of payments related to certain strategic prior year-end purchases as well as the impact of annual benefits re-verification on accounts receivable.
Cash Flows from Investing Activities
The increase in cash used in investing activities during the three months ended March 31, 2025 was primarily related to the Intramed Plus acquisition with no comparable activity during the three months ended March 31, 2024.
Cash Flows from Financing Activities
The increase in cash used in financing activities is primarily related to the Company’s $100.0 million repurchase of common stock during the three months ended March 31, 2025, whereas the three months ended March 31, 2024 activity primarily related to the Company’s $40.0 million repurchase of common stock.
Critical Accounting Policies and Estimates
The Company prepares its unaudited condensed consolidated financial statements in accordance with GAAP, which requires the Company to make estimates and assumptions. The Company evaluates its estimates and assumptions on an ongoing basis. Estimates and assumptions are based on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making assumptions about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. The Company’s actual results may differ from these estimates, and different assumptions or conditions may yield different estimates.
There have been no material changes to the Company’s critical accounting policies and estimates as presented in our Form 10-K, which are hereby incorporated by reference.
27
Item 3.     Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes to our exposure to market risk from those included in our Form 10-K, which is hereby incorporated by reference.
Item 4.     Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures (as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer, management evaluated the effectiveness of the Company’s disclosure controls and procedures as of March 31, 2025. Based on that evaluation, the Company’s Chief Executive Officer and its Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2025.
Changes in Internal Controls over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended March 31, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
28
PART II
OTHER INFORMATION
Item 1.     Legal Proceedings
For a summary of legal proceedings, refer to Note 13, Commitments and Contingencies, of the unaudited condensed consolidated financial statements included in Item 1 of this Form 10-Q.
Item 1A.    Risk Factors
There have been no material changes to the risk factors affecting our business, financial condition or results of operations from those set forth in Part I, Item 1A. “Risk Factors” in our Form 10-K. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition and/or operating results.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
On January 10, 2025, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $500 million of common stock of the Company. This program has no specified expiration date.
The following table provides certain information with respect to the Company’s repurchases of common stock from January 1, 2025 through March 31, 2025:
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
January 1, 2025 - January 31, 2025— $— — $500,000,000 
February 1, 2025 - February 28, 20251,499,849 31.70 1,499,849 452,455,293 
March 1, 2025 - March 31, 20251,546,366 33.92 1,546,366 400,000,895 
3,046,215 $32.83 3,046,215 $400,000,895 
Item 5.    Other Information
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements
No director or officer of the Company has adopted, modified or terminated a Rule 10b5-1 plan or non-Rule 10b5-1 trading arrangement during the three months ended March 31, 2025.
29
Item 6.     Exhibits
(a) Exhibits.
Exhibit Number Description
31.1
31.2
32.1
32.2
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Labels Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104XBRL Formatted Cover Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 OPTION CARE HEALTH, INC.
 
Date: April 29, 2025
/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Executive Vice President
(Principal Financial Officer and Duly Authorized Officer)
30
 EX-31.1 2 ex311-q12025.htm EX-31.1 Document

EXHIBIT 31.1 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John Rademacher, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 29, 2025


/s/ John Rademacher
John Rademacher
President, Chief Executive Officer and Principal Executive Officer


 EX-31.2 3 ex312-q12025.htm EX-31.2 Document

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Shapiro, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 29, 2025

/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Principal Financial Officer


EX-32.1 4 ex321-q12025.htm EX-32.1 Document

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
    In connection with the Quarterly Report of Option Care Health, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Rademacher, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 29, 2025

/s/ John Rademacher
John Rademacher
President, Chief Executive Officer and Principal Executive Officer

    


 EX-32.2 5 ex322-q12025.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
    In connection with the Quarterly Report of Option Care Health, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Shapiro, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 29, 2025

/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Principal Financial Officer





EX-101.SCH 6 bios-20250331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - BUSINESS COMBINATIONS link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - INDEBTEDNESS link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - FAIR VALUE MEASURMENTS link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - BUSINESS COMBINATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - INDEBTEDNESS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - BUSINESS COMBINATIONS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - BUSINESS COMBINATIONS - Preliminary Estimate of the Allocation Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - LEASES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - INDEBTEDNESS - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - INDEBTEDNESS - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - INDEBTEDNESS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - INDEBTEDNESS - Long Term Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - SEGMENT REPORTING (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bios-20250331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bios-20250331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bios-20250331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Minimum Payments Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Adjustments to reconcile net income to net cash used in operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Acquisitions Goodwill, Acquired During Period RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Assets under development Asset under Construction [Member] Cover [Abstract] NET DECREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Maturities of Lease Liabilities, Operating Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Percentage of the combined company held Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Ownership interest Equity Method Investment, Ownership Percentage All Trading Arrangements All Trading Arrangements [Member] Legacy Health Systems Legacy Health Systems [Member] Legacy Health Systems [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Cash paid for income taxes Income Taxes Paid, Net Investments in equity-method investees Equity Method Investments Cost of Goods and Service, Product and Service Benchmark Cost of Goods and Service, Product and Service Benchmark [Member] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Income Tax Examination [Line Items] Income Tax Examination [Line Items] Derivative [Table] Derivative [Table] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Amount and Location of Derivatives in the Balance Sheet Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Cash paid for operating leases Operating Lease, Payments, Use LEASES Lessee, Operating Leases [Text Block] Common stock, shares, outstanding (in shares) Balance, beginning of the year Balance, end of the period Common Stock, Shares, Outstanding Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Total noncurrent assets Assets, Noncurrent Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Plan Name [Domain] Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Total gross intangible assets Finite-Lived Intangible Assets, Gross Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Treasury stock, shares, acquired (in shares) Treasury Stock, Shares, Acquired Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Supplier [Domain] Supplier [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Treasury Stock Treasury Stock, Common [Member] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Other segment items Other Cost and Expense, Operating Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Performance stock unit awards Performance Stock Unit [Member] Performance Stock Unit Adjustment to Compensation, Amount Adjustment to Compensation Amount Paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Earnings per common share, diluted Earnings Per Share, Diluted [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Release of valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Antidilutive securities excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Operating lease cost Operating Lease, Expense Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents - beginning of the period CASH AND CASH EQUIVALENTS - END OF PERIOD Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Concentrations of Business Risk Concentration Risk, Business Risk, Policy [Policy Text Block] Concentration Risk, Business Risk, Policy [Policy Text Block] HC I Incentive Units HC I Incentive Units [Member] HC I Incentive Units [Member] CURRENT ASSETS: Assets, Current [Abstract] Goodwill (2) Goodwill - net book value, begging of period Goodwill - net book value, end of period Goodwill Stock-based compensation tax withholdings Payment, Tax Withholding, Share-Based Payment Arrangement OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX: Other Comprehensive Income (Loss), Net of Tax [Abstract] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Treasury stock, at cost (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Goodwill [Roll Forward] Goodwill [Roll Forward] Total depreciation expense Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Other financing activities Proceeds from (Payments for) Other Financing Activities Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] NET COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Attributable to Parent First Lien Term Loan First Lien Term Loan First Lien Term Loan [Member] First Lien Term Loan [Member] Preferred stock, shares, outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Earnings per common share, basic Earnings Per Share, Basic [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Repayments of debt principal Repayments of Debt Purchase of company stock, and related excise taxes Payments for Repurchase of Common Stock and Related Excise Taxes Payments for Repurchase of Common Stock and Related Excise Taxes Total liabilities Liabilities Salaries, benefits, and other employee expense Labor and Related Expense Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Intangible assets useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Revolver Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current portion of operating lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares, issued (in shares) Common Stock, Shares, Issued Senior Notes Second Lien Term Loan [Member] Second Lien Term Loan [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration ​risk Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, gross Property, Plant and Equipment, Gross Interest rate cap designated as cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Exercise of stock options, vesting of restricted stock, and related tax withholdings Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Business acquisitions, net of cash acquired Purchase price, net of cash acquired Purchase price, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Weighted average interest rate paid on term loans during period Long-Term Debt, Weighted Average Interest Rate, over Time Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted average number of common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Total stockholders’ equity Equity, beginning balance Equity, ending balance Equity, Attributable to Parent Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Interest expense, net Interest Expense, Nonoperating Deferred income taxes - net Deferred Income Tax Expense (Benefit) Interest rate cap designated as cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of Goodwill Schedule of Goodwill [Table Text Block] PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Computer software, purchased and internally developed Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Equity in earnings of joint ventures Investment Income, Net Undrawn letters of credit issued and outstanding Letters of Credit Outstanding, Amount Selling, general and administrative expenses Selling, General and Administrative Expense OTHER COMPREHENSIVE (LOSS) INCOME Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Interest rate cap designated as cash flow hedge Interest Rate Cap [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Depreciation expense in cost of revenue Cost of Sales [Member] Governmental Healthcare Programs Government Contracts Concentration Risk [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Balance Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus 2029 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Intangible assets, net Finite-Lived Intangible Assets, Net, Excluding Customer Lists Finite-Lived Intangible Assets, Net, Excluding Customer Lists Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Effective rate on term loans at end of period Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Treasury stock acquired, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Accounts payable and other liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable and Other Liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable and Other Liabilities OTHER INCOME (EXPENSE): Other Expense, Nonoperating [Abstract] Depreciation and amortization expense Depreciation, Amortization and Accretion, Net Amortization expense for intangible assets Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Total intangible assets, net Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Discount Debt Instrument, Unamortized Discount Leasehold improvements Leasehold Improvements [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] BUSINESS COMBINATIONS Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount NONCURRENT ASSETS: Assets, Noncurrent [Abstract] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] INCOME BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Intramed Plus, Inc Intramed Plus, Inc [Member] Intramed Plus, Inc Medical Supply Vendors Supplier Concentration Risk [Member] Non-PEO NEO Non-PEO NEO [Member] Purchase of company stock, and related tax effects Stock Repurchased During Period, Value, Including Related Tax Effects Stock Repurchased During Period, Value, Including Related Tax Effects Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Earnings per share, diluted (in dollars per share) Earnings per common share, diluted (in dollars per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Non-cash operating lease costs Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name State jurisdiction State and Local Jurisdiction [Member] Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of operating segments Number of Operating Segments Customer [Axis] Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Accrued expenses and other current liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Accounts receivable, net Increase (Decrease) in Receivables Stock-based incentive compensation expense Share-Based Payment Arrangement, Noncash Expense Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory INCOME TAX EXPENSE Income tax expense Income tax expense Income Tax Expense (Benefit) Notional amount of derivative Derivative, Notional Amount Total derivative assets Derivative Asset Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Depreciation expense in operating expenses Operating Expense [Member] Management fee income Infusion services net revenue Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Total other expense Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities OPERATING INCOME Operating Income (Loss) Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Equity Method Investments Equity Method Investments [Policy Text Block] TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity Other adjustments Other Operating Activities, Cash Flow Statement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and employee benefits Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Hedging Designation [Axis] Hedging Designation [Axis] DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Number of infusion sites Number Of Infusion Sites Number Of Infusion Sites Schedule of Long-term Debt Maturities Schedule of Maturities of Long-Term Debt [Table Text Block] Increase in operating lease right-of-use asset and lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Inventories Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Equipment, furniture and other Equipment, Furniture, And Other [Member] Equipment, Furniture, And Other [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Due to joint ventures Accounts Payable, Other OPERATING COSTS AND EXPENSES: Operating Expenses [Abstract] Fair value identifiable assets and liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Purchase price Business Combination, Consideration Transferred LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Derivative, term of contract Derivative, Term of Contract Infusion pumps Infusion Pumps [Member] Infusion Pumps [Member] Second Lien Term Loan Junior Lien [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Concentration Risk [Table] Concentration Risk [Table] Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Principal Amount Total Long-Term Debt, Gross Exercise Price Award Exercise Price EARNINGS PER SHARE Earnings Per Share [Text Block] Accrued compensation and employee benefits Increase (Decrease) in Employee Related Liabilities Arrangement Duration Trading Arrangement Duration LEASES Lessee, Finance Leases [Text Block] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other revenue Other Income Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Accounts payable Increase (Decrease) in Accounts Payable, Trade All Individuals All Individuals [Member] Trademarks/names Trademarks and Trade Names [Member] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Equity in earnings of joint ventures Equity in earnings of joint ventures Income (Loss) from Equity Method Investments Treasury stock; 20,631,828 and 17,585,613 shares outstanding, at cost, as of March 31, 2025 and December 31, 2024, respectively Treasury Stock, Common, Value 2025 Long-Term Debt, Maturity, Remainder of Fiscal Year Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] First Lien Term Loan Senior Lien [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Total noncurrent liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restricted stock awards Restricted Stock Award [Member] Restricted Stock Award [Member] Local Phone Number Local Phone Number Number of shares authorized to be repurchased (in shares) Share Repurchase Program, Authorized, Number of Shares Four Vendors Four Vendors [Member] Four Vendors Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Supplier [Axis] Supplier [Axis] Accounts Receivable, Benchmark Accounts Receivable, Benchmark [Member] Accounts Receivable, Benchmark Valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Deferred income taxes Deferred Income Tax Liabilities, Net Number of service locations Number Of Service Locations Number Of Service Locations Interest expense, net Interest Expense [Member] Share repurchases Stock Repurchased During Period, Shares Rebate receivable Contract with Customer, Receivable, after Allowance for Credit Loss Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Finite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Change in unrealized (loss) gain on cash flows, income tax benefit (expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Emerging Growth Company Entity Emerging Growth Company Income Tax, Examination [Table] Income Tax, Examination [Table] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Number of infusion sites, including advances practitioner capabilities Number Of Infusion Sites, Including Advances Practitioner Capability Number Of Infusion Sites, Including Advances Practitioner Capability Patients Patient Customer [Member] Patient Customer [Member] Credit Agreements, Entered Into 2019 Credit Agreements, Entered Into 2019 [Member] Credit Agreements, Entered Into 2019 [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2018 Plan 2018 Plan [Member] 2018 Plan STOCKHOLDERS’ EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Current portion of long-term debt Less: current portion Long-Term Debt, Current Maturities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based incentive compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Government Healthcare Programs Government Healthcare Programs [Member] Government Healthcare Programs SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Second Lien Credit Agreement First Lien Credit Agreement, Second Amendment [Member] First Lien Credit Agreement, Second Amendment City Area Code City Area Code CURRENT LIABILITIES: Liabilities, Current [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Markets for Identical Item (Level 1) Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Preferred Stock Preferred Stock [Member] 2028 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, net of discount, deferred financing costs and current portion Total long-term debt Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other amortizable intangible assets Other Intangible Assets [Member] INCOME TAXES Income Tax Disclosure [Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four EARNINGS PER COMMON SHARE: Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Lien Category [Axis] Lien Category [Axis] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories Increase (Decrease) in Inventories Schedule of Debt Schedule of Debt [Table Text Block] 2027 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Present value of lease liabilities Operating Lease, Liability Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Reportable Segment Reportable Segment [Member] Reportable Segment Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Total debt instruments Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Accounts receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization expense Depreciation and amortization expense Depreciation, Depletion and Amortization GROSS PROFIT Gross Profit Fair Value as of Grant Date Award Grant Date Fair Value Largest Payer Largest Payer [Member] Largest Payer Company's Largest Payer Customer Concentration Risk [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Debt Issuance Costs Debt Issuance Costs, Net INDEBTEDNESS Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] STOCKHOLDERS’ EQUITY: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Net Revenue Earned by Category of Payer Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock; $0.0001 par value: 250,000,000 shares authorized, 184,376,321 shares issued and 163,744,493 shares outstanding as of March 31, 2025; 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024 Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other noncurrent assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Joint Venture Corporate Joint Venture [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Schedule of Common Stock Outstanding Roll Forward Schedule of Common Stock Outstanding Roll Forward [Table Text Block] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March 31, 2025 and December 31, 2024 Preferred Stock, Value, Issued Earnings per share, basic (in dollars per share) Earnings per common share, basic (in dollars per share) Earnings Per Share, Basic Cash acquired Less: cash acquired Cash Acquired from Acquisition Operating lease liabilities Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Stock option awards Equity Option [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] TOTAL ASSETS Assets Distribution from equity method investments Distributions received from the investees Proceeds from Equity Method Investment, Distribution COST OF REVENUE Cost of Goods and Services Sold Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Government payers Government Customer [Member] Government Customer [Member] Termination Date Trading Arrangement Termination Date Other noncurrent assets and liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Related Party Transaction [Table] Related Party Transaction [Table] NET REVENUE Net revenue Total Option Care Health revenue Revenues 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Long-Term Debt, Maturity, Year One STOCK-BASED INCENTIVE COMPENSATION Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Schedule of Acquired Identifiable Assets and Assumed Liabilities Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Estimated Fair Values of Debt Obligations Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Share-based compensation expense Share-Based Payment Arrangement, Expense NET INCOME Net income Net income Net income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Available borrowing capacity Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Number of service locations, including ambulatory infusion suites Number Of Service Locations, Including Ambulatory Infusion Suites Number Of Service Locations, Including Ambulatory Infusion Suites Income (Expense) [Abstract] Income (Expense) [Abstract] Income (Expense) REVENUE Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Equity award issuances Shares Issued During Period, Shares Shares Issued During Period, Shares Shares repurchased Treasury Stock, Value, Acquired, Cost Method Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Name Forgone Recovery, Individual Name 2025 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted-average remaining lease term, operating leases Operating Lease, Weighted Average Remaining Lease Term Commercial payers Commercial Customer [Member] Commercial Customer [Member] Document Period End Date Document Period End Date Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Insider Trading Arrangements [Line Items] Lien Category [Domain] Lien Category [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cost of net revenues - drugs Cost of Revenue Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Referral sources Customer Lists [Member] Customer [Domain] Customer [Domain] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Referral sources, net Finite Lived Customer Lists, Net Finite Lived Customer Lists, Net Referral sources (1) Referral Sources [Member] Referral Sources Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Related Party [Axis] Related and Nonrelated Parties [Axis] Weighted average common shares outstanding, basic (in shares) Weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $783 and $(454), respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 bios-20250331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 bios-20250331_g1.jpg GRAPHIC begin 644 bios-20250331_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#T17AI9@ 34T *@ @ ! $[ ( M . (2H=I 0 ! (6)R= $ < 0T.H< < @, /@ M FMC.60G/SX-"CQX.GAM M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS M.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z M#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5 M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @* M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@ K &K P$B (1 0,1 ?_$ !\ $% 0$! M 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" M P $$042(3%!!A-180'EZ@X2% MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ M ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,082 M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3 ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C MY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D&W8^7&?>EHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DSB@G%>9^-_ M'4HGDTS1I"H0[99UZY]!_C0=>$PE3%U/9TSK]8\8Z/HK&.ZN0TP_Y91_,P^O MI^-Q+@9KS$G(GY7'N/ZTTSEQ>04W'FP[L^S/H>BLCPYXAM?$6EK=VK -TDC)Y1O M2M?(]:H^/G"5.3C)6:"BBB@@**** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH CGFCMH7FGD6..-2SNQP% [DUXMXT_:!@LKB2R\)6Z7;J M2INYL^6#_LCO7/?'?XDSWNJ/X4T>=DM(#B]=#_K7_N?0?J:\=0LPWRX!\N3NK&N05]95AJ!E41S'YQT/K5LR5S6Y&:[O3/'VKV+ 7+K>1]Q)PWYBO*O,]ZZ:TE\ZTC?U45Y M./YZ352#L+ZO0Q*:J13/W&GW:7-I(8Y4 M.01_*O:?#^LQZYI,=W'\K'AU_NMW%:X3%>V7++<^0S7*W@WSPUB_P-2BBBN\ M\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ%J0T?PWJ&HMQ] MEMWEY]E)K2KEOB7$\WPS\0)$/F-C)C\JJ"O))B>Q\93W?'%0H1YI;E:TL+FZQY$ M+./7''YUM6_AB\?[\D4?XEJU[;"J /05IPMTKBF<\\YQ%_/A2]0922 M&3VR5/ZU0GL;BS;%S"T?N1D?G7J>D^&]1UB1$MH=H;^.3Y1CUKJO^%2M/#MN MM14YZJL61^IKCG*'5GH8+-\=>\H\R^X^?02C!EX(/&*U4GWQJWK77>.OA/?> M&;!M3LIEN[13^]55(:(?WL=Q_*N#M9/W)'H:RLFM#[C!XI58\T>I?WYKIM); M.G1?C7(;\GK7964?DV<2=PHS7EY@KTTCW<&W*39:!KN_AE?LE_ MXK@@:ZWX<*3XHX[0MFO(PR<:T;$YM!2P<[]CUNBBBOHC\U"BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ JMJ-FFH:;<6(+ZRNUQ+:S-&N?0'@_E6C;. U4KW4) M=3U.XO;ABTMQ(9&)/J&5C@CO=1CR[# M9=T%O\ .X/<]A7K\<@( KRL5-Q?*C?#P4M6=3X> MLUCM#.1\TG3V%;-<5X&UT3276FW#XD25FBR>HSR*[3(KR:=15(\R/K9X>6&? MLY$=S;QW=M)!.H>.12K*1P0:^5/%>@-X9\4W^F_P)+NB/JAY%?4VHW]OINGS M7EW((X84+LQ[ 5\P:SBKT _*NB#Y4VSU\IIU)S?*M# M/T:T-W?!F'[J/ECZGL*ZT&JMG:QV< BB& .I]35BO+Q,_:2OT/O<-1]C"SW) M :]'^&.FD+>V5K+>W*0PC);J?0>M>N^#PMI$;*/[BKD?7O7 MG4J].&*C3>[/'SVMRX9TX[O?T.HHHHKZ$^ "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ KF/B06'PWUWR\[OL4F,?2NGJEK%@NJ:-=V,G*W$+1G\ M1BJB[23)DKQ:/B>*2K4?\ BFE//L*[5+G'>N%\$W _X1FW [,V?SKI5N>.M>)6C>HR(5.7 M0SWGFL-7::V)S32U-&5;%V5HH=I6GQ6$>V,98_ M><]374^'<_VIQ_<-8<(KI/#5N3)).>F-HKR\OYZV.@WJ[W/F,?4O3DY=3HZ* M**_1#Y<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PSXX_# M*>\=O%.@PF215_TV!!RP'_+0#O[BO E?!YXQ7W>0&!!&0>QKS#QK\#M#\2RR MWFEN=*OGY)C7,;GW7_"O4PN,4%R5-C@Q&%YWS1/)?A]?B73)[8GYHGW#Z&NQ M$IK$T[X/^-O"^N)-!;V^H6C?)(UO. =OKM;!_G6H^Z*1HY 5=3A@1R#3JN$I MW@[GS^(H3I2U6Y,9,CGI21XSMJ O2%_>O-QF"ABH6>CZ,]+*,XKY95YH:Q>Z M-%$JS&E9<5\T>-XWC\JO0ZG:_P ;,GU&?Y5\;B1^E8?B+ XF-^? ME?9Z&E$O2K<2TND64VL([Z>GFJAPS= #^-=)9>$YB0;N14'=4Y->:L#BJDN5 M09=7'X?EYE-/T,ZPM);N98X1DGJ?2NWM+5+.V6*/HHZ^II+2Q@LHMD"!?4]S M5BOJ,MRU816FP4445[)Q!1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% 1FN)\7^"O[29[[2P%NNKQ]!)[_6NVHJHR<7 M=&5:C"M'ED?/EQ!/:3-#M>]W^CV.J)MO[6.88X++R/QK MD^'&A.^X1S)ST$G%=*KKJ>)/*ZB?N.YY#FM[P[X2O]?G5@AAM0?GF8:^!/"'B M[1/'.K:CKVJ_:+"X5@B><7WDME3M/W<"O2J "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ J*YN$M;66XESLB0NV/0#-2U1UO_D W M_P#U[2?^@F@"AX3\7:=XRTN2_P!(\WR8YC"WF+M.X '^M;M>4_L]_P#(AWO_ M &$9/_05KU:@ HHHH **** "BBB@ HHHH P/%OC'3?!MC!=ZOYOESS"%/*3< M=V"?Z5MP3+<6\4?M"?\BKI/_817_P! :O4=+_Y!%I_UP3_T M$4 0Q:[IDVL2:5%>PM?QKN>W#?.H]$+%=2UR7[P/*0_4#J>_H.]=_?W0LM/N+END,;.?P&:\@^!-J-5U'Q%X MFO!YEU/<^4CMR5!RS8_,?E0,NC2_C*4^UG6-,$G7[+M&/I]W'ZUI^!_B5=ZG MKTGAGQ?8KINN1YV!>$FP.V>AQS[UZ/7BWQUMO[)U3P]XGLOW=W!<>677C./F M&?U'XT =1\6_&FJ>#-)TZYT=H5:XN#'(98]PVXS6'_PEWCWQS+*W@2VM;+2X MFV"^NAS,PZD9S@9]JJ?'^7[9X-T*5/\ EM/N'XIG^M>J^&]-AT?PWI]C;($C MA@10 .^.3^= 'D]SXV^(GP_NH9?&MG;ZEI-_&MAX'T(W]\#+*[;+>W0_-*_I[# MU->?_"O_ )*YXT_WO_:AJOXK3_A*_P!H;2-%NOWEG81B5HCT.%+G]0* ZENR MN/BYXKMUU"VFL-#M91NBA=/F([=03^>*!\0/&'@/5;>V^(MI!=:=<-M74+0? MP^,FL_VAK-A):17]^EV;;3;6%"I8[B,L?0 "NF^! M^K2:G\-;>.9BS6/;D?UK9^''Q%N_$=_=Z#XELUL= +!=0U($K+.XRD1[X'3CN3Q5)M,^,\*?:UU73II!\WV M;Y>?;[N/UJ?X!Z*D/A2XUN8![O4)VW2'D[0>GYY->LT#/._A]\29O$6H7&@^ M([,:=KEKG=$,A9 .I /0^U/^(/Q$N?#VHVF@^'+-;_7+W_5QM]V,'N1W-=A_ MPC^E?VW_ &O]AA_M#;M^T;?GQ]:P9/ FF0^/SXRGO)A6HVXR/2@# MDQH?QBN!]I?Q!IT$AY%N%&![?=Q5GP?\0]>B\9'PAX\LXH=089@N81A9.,\C MH<]B*W]9^*_@[1':.XU>.:5>#':J96_3C]:\OU#QE9>,OC3X7O=,M+JWBA;R MM]P@4R?,3D#TH ]A\>:U=^'O!.HZIIQ07-O'N0NNX9SZ5YQI7Q*\9>+]+L[# MPC96\VHK%OO[Z5-L4+$\*!TSCZ_2NW^+'_)+]9_ZX?U%4/@GIT5C\,K&2-0) M+IFFD;'+$G _04 6_#EWXD\.Z%J5_P#$?4+1XX<2))!C"KCD< )4 6S;D@!8?[0UM+/7--C.9O*^ M\@]<@ CZX(KT[POXFT_Q;H4.J:6Y,4G#(WWHV[J?>N.E^-O@J>%XIFO'C<%6 M5K-B"#U%I7@-@<=N"* /=ZHZW_R +_\ Z]I/ M_035ZJ.M_P#( O\ _KVD_P#030(\ ^&GC+4]*\*/H/A33QJ&MW=])(%?_5P1 M[5&]OQ%=7<<'Z5L^+O%FG^# M=!DU/4V.U?ECB7[TK]E%>:?#I!9_'CQ;:0C9$8F;:/7S%_\ BC65\9-8M9OB M?HFG:P[C2K/9+.J*6)RSU;XK>.(?[0T=;+0]/DYA$OWF'KD@D_ M7 %$OC;Q[\/[J ^/+.'4=*D<(;NU W)[Y&,_0BMV/XW^"XHU2-[U%48519L M!69XF^+/@CQ#X:O]+G>]87,+(N;-N&Q\I_ XH ]2T_4+;5-.@OK&59K>= \; MKT8&O-O$_P 0]>U#Q?+X4^'UI#->6_%U=SX';CN3WJO^S]JL]WX.NM/N M"W^A3_N\CHK#./SS73^'_!NC> ]3U35SJ+_\3!M\K7;J OS%C@\>M '+/HGQ MBM$-U%K^GW,@&3;E1@^PRN*W/AM\1+GQ7->Z1KMFMEK.GG]\B9"N,X) /0@] M13]6^,_@S3)&B34'OI1QLLXC)S]>GZUPOPUUF'7_ ([:SJ=M;RVT5S:NXBF& M&'*=0* -S]H3_D5-)_["*_\ H#5T_B'_ (3/^QM(_P"$(^Q;O)'VC[5CIM7; MC]:YC]H3_D5-)_["*_\ H#5ZCIG_ "";3_K@G_H(H ^=M,_X3W_A<.H?9/[/ M_P"$A\@^?NQY6SCI[]*]:M?^$K_X0#7_ /A-?LGVK[--Y7V7&-GEGK[YKEM" M_P"3E]9_Z]#_ .RUZ9XI_P"10U?_ *\9O_0#0!X5\-?&6KV/@V'P[X/T];[6 M9YWD9I/]7;IQAFKJ+I/C-I,+ZBUUI]\L8WO;1JK<=P!@?H:D_9XTV&+P?=Z@ M$'G7%QL+8YVJ!Q^M>O'I0!R'PZ\>0^.M#>X:#[+?6S>7=09R%;U'L:S->\0: MB-01HIY8XY)I88HH6*[?+=5R2 ?F8MGYOE Q]:YOX4 6WQ:\:6<0VQ+,Y"CH M,2G_ !KTZ]\-6MW=2SK)- TPQ*(FP'Z!R/04 2^'[Z>^T]_M>#-!,\#N MHX@14U6U-]I%W:CK-"Z#\017DW[/UR+ M:UU_19CLN;6[#E#UP1M)_-:]DKRGQA\/]:T[Q9_PE_P_D1+YL_:;1SA9O7'; MGN*!GJU>,?'VZ%\^@:!:_/=W%SO"#K@_*/U/Z5:_X6)\1&A^S+X$E%WC'FDG M9GU]/UJYX*^'VKS>*3XO\>3+-JG_ "[VZ'*P<8S^ / H#8R/CU']B\&^'X^O MD7 7Z[4'^%>N:1=Q7VC6=U;N'CFA1U([@@5Y5^T.H;P]HRGH;P@_]\TR"#Q[ M\.XQ:Z!8#7M#;Y[="GILM[:,(H[GU)]R>: /+M4_Y.H]"#77^!=4\5ZP]]=^*M,73(#L6TM\_,. MNXG]* .+^%?_ "5SQI_O?^U#5?5Y!H'[36GWEW\D%_#Y:NW RR%>OU 'XUO_ M ^\+ZOH_P 1_%&I:C:&&TO6S!(6!W_.3_*MOXC> 8?'&CQK%+]FU&U;?:W' MH?[I]C0'4[+--0?XF8;0/S-!W)%5Y_#GC;XHZA;_ /"66XT31(9-YME/SR?AZ^YH W_@3ILE MC\-HY95*_:IWE4$=5X /Z5B_!7_D);G5K,P0WEP7@8L#O&]CGCV- 'IU>-:K_P G0V'_ M %Z)_P"@M7LM>8:CX6UB;X^6FOQV9;3([94:?<, A6&,=>] 'I]<_P".M/DU M7P'K-E ,R2VCA!ZG&1_*N@I",C!Y!H$>6_ /58[OP(^GY FL9V5T/4!N0:]3 MS7CVN> ?$GA'Q9-XD^'926.X):XT]S@-GD@#N._J*?)\0/B1VK736RW,)G49,0<;A^'6O%KR+4OBM\3-4T6XOY;/0](< MH\4+8,A!QS]3FNC^'?PYU#3-:N/%'B^=;G6KG. #D19Z\^O;VK+\1>$?%/A/ MQY=>*O \*WT5]EKJS8\DGK@=^>: .ST3X8>$M!53:Z3#)(O_ "UG'F-^M<#X MWO+23X^^%;*S,8-F%614 0LQ('Y?SJ])XK^*6O+]DTWPNFDLXVMK?!_7M+72];T&Z6_UZ"9I[QYGQYSDY&,]ATH ] ^*__),-9_ZX_P!13?A' M_P DNT;_ *XG^9K/U2W\5>*/A1JMIK&E1VVKRYCCMXI 0ZC&#G/UK<^'.DWF MB> =,T_4HO)N8(RLB9!PSM'CGA5U81*Q'N#S7DFGZ M=\1?ABSV6DV:^(-&#EHE!^=!].HH ]@_LG3?^?"V_P"_*_X5F:/KGAF^UF[T M_19K1KZT)6>.&,!E]><^)_BCXGB:PTKPV=%$HVOGY5V?PZ M\ V_@?1WC:3[1J%R=]S<8ZGT'M0!V-4=;_Y -_\ ]>TG_H)J]53587N-'O(8 M5W220.JCU)4@4"/-/V>_^1#O?^PC)_Z"M>K&O/?@UX;U3PQX1NK/6[;[-/)> MO*J;@'-:OD4V4Y1' M+C*\$J<_]] UTOA/PKK&G?&CQ#K=Y:&/3[R%EAFW [B70].O0&NH\=^"[/QO MX=;3[IO*F0^9;S@>(/%M]-]@CG,=O90OM48YQ[ #'UKUKPQX1T_P ,>%X]$M%WQ;") M78BW,OF)&#\R?AV../?% 'INC^ _#.@(/ M[.TBVC91_K'3(9K5U>(PR(K+T.TH./RJY/>?$_QNIL%T MR/PW8R_+-.[?O-O?'>J,OPV\2^ _%L&L> X8M0A^SB*6*=\,3CYLY]2,T :? M[0G_ "*FD_\ 817_ - :O4M+_P"03:?]<$_]!%>:_$S0/$?C#P+HB1::/[22 MY6:Y@5QB/Y2#R>O)KTRPC:'3;:.08=(E5AZ$ 4 >2Z#_ ,G+ZS_UZ'^2UZ9X MI_Y%#5_^O&;_ - ->7^*M&\6>&?BP_BOPWI)U2"ZBV/&AZ<8(/IT!S76Z,_B MS7/!>MGQ+8QVEW=12):6J$952A !]\T 8_[/_P#R3<_]?;_R%>HUP/P=\.ZG MX9\$?8=:MS;W'VAWV%@>"!Z5WU 'C'PP_P"2U>-O^NK_ /HVO9Z\Q\!>%-8T M?XH>*=5U"T\JSOI'-O)N!W@R9''TKTZ@ HHHH$%%%% !BBBB@#R']H-6?0=& MV*6_TT]!G^&O6+,?Z%#G_GFO\JD>*.0 2(K@=-PS3L4 &**** "BBB@ HHHH M ,4444 %%%% !1110 4444 %&*** "BBB@ Q1110 4444 %%%% !1110 444 M4 %%%% !1110 8HHHH *,444 %%%% !1110 4444 %%%% !1110 4444 ?_9 end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2025
Apr. 25, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2025  
Document Transition Report false  
Entity File Number 001-11993  
Entity Registrant Name OPTION CARE HEALTH, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 05-0489664  
Entity Address, Address Line One 3000 Lakeside Dr.  
Entity Address, Address Line Two Suite 300N,  
Entity Address, City or Town Bannockburn,  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60015  
City Area Code 312  
Local Phone Number 940-2443  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol OPCH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   163,747,250
Entity Central Index Key 0001014739  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
CURRENT ASSETS:    
Cash and cash equivalents $ 171,372 $ 412,565
Accounts receivable, net 476,649 409,733
Inventories 369,034 388,131
Prepaid expenses and other current assets 82,320 112,198
Total current assets 1,099,375 1,322,627
NONCURRENT ASSETS:    
Property and equipment, net 131,264 127,367
Operating lease right-of-use asset 90,950 86,528
Intangible assets, net 24,427 16,993
Referral sources, net 312,586 284,017
Goodwill (2) 1,605,930 1,540,246
Other noncurrent assets 43,981 43,965
Total noncurrent assets 2,209,138 2,099,116
TOTAL ASSETS 3,308,513 3,421,743
CURRENT LIABILITIES:    
Accounts payable 528,848 610,779
Accrued compensation and employee benefits 49,664 63,028
Accrued expenses and other current liabilities 106,177 77,783
Current portion of operating lease liability 22,463 22,044
Current portion of long-term debt 6,512 6,512
Total current liabilities 713,664 780,146
NONCURRENT LIABILITIES:    
Long-term debt, net of discount, deferred financing costs and current portion 1,104,160 1,104,641
Operating lease liability, net of current portion 89,825 84,776
Deferred income taxes 48,946 47,576
Other noncurrent liabilities 1,084 366
Total noncurrent liabilities 1,244,015 1,237,359
Total liabilities 1,957,679 2,017,505
STOCKHOLDERS’ EQUITY:    
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March 31, 2025 and December 31, 2024 0 0
Common stock; $0.0001 par value: 250,000,000 shares authorized, 184,376,321 shares issued and 163,744,493 shares outstanding as of March 31, 2025; 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024 18 18
Treasury stock; 20,631,828 and 17,585,613 shares outstanding, at cost, as of March 31, 2025 and December 31, 2024, respectively (608,711) (507,598)
Paid-in capital 1,234,800 1,231,435
Retained earnings 716,078 669,336
Accumulated other comprehensive income 8,649 11,047
Total stockholders’ equity 1,350,834 1,404,238
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 3,308,513 $ 3,421,743
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 12,500,000 12,500,000
Preferred stock, shares, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares, issued (in shares) 184,376,321 183,846,725
Common stock, shares, outstanding (in shares) 163,744,493 166,261,112
Treasury stock, at cost (in shares) 20,631,828 17,585,613
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
NET REVENUE $ 1,332,972 $ 1,146,052
COST OF REVENUE 1,069,920 907,552
GROSS PROFIT 263,052 238,500
OPERATING COSTS AND EXPENSES:    
Selling, general and administrative expenses 168,118 154,742
Depreciation and amortization expense 15,746 14,728
Total operating expenses 183,864 169,470
OPERATING INCOME 79,188 69,030
OTHER INCOME (EXPENSE):    
Interest expense, net (13,231) (13,202)
Equity in earnings of joint ventures 1,729 1,125
Other, net (4,130) 2
Total other expense (15,632) (12,075)
INCOME BEFORE INCOME TAXES 63,556 56,955
INCOME TAX EXPENSE 16,814 12,164
NET INCOME 46,742 44,791
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:    
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $783 and $(454), respectively (2,398) 1,551
OTHER COMPREHENSIVE (LOSS) INCOME (2,398) 1,551
NET COMPREHENSIVE INCOME $ 44,344 $ 46,342
EARNINGS PER COMMON SHARE:    
Earnings per share, basic (in dollars per share) $ 0.28 $ 0.26
Earnings per share, diluted (in dollars per share) $ 0.28 $ 0.26
Weighted average common shares outstanding, basic (in shares) 165,460 173,928
Weighted average common shares outstanding, diluted (in shares) 166,804 175,624
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Change in unrealized (loss) gain on cash flows, income tax benefit (expense) $ 783 $ (454)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 46,742 $ 44,791
Adjustments to reconcile net income to net cash used in operations:    
Depreciation and amortization expense 16,373 15,305
Non-cash operating lease costs 9,002 7,663
Deferred income taxes - net 1,370 2,964
Amortization of deferred financing costs 1,147 1,132
Equity in earnings of joint ventures (1,729) (1,125)
Stock-based incentive compensation expense 8,801 9,605
Distribution from equity method investments 0 750
Other adjustments (949) 108
Changes in operating assets and liabilities:    
Accounts receivable, net (56,788) (195,992)
Inventories 21,790 32,056
Prepaid expenses and other current assets 28,444 4,878
Accounts payable (88,101) 59,223
Accrued compensation and employee benefits (14,458) (49,884)
Accrued expenses and other current liabilities 27,503 6,811
Operating lease liabilities (7,956) (6,651)
Other noncurrent assets and liabilities 1,595 (418)
Net cash used in operating activities (7,214) (68,784)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Acquisition of property and equipment (9,371) (5,820)
Business acquisitions, net of cash acquired (117,322) 0
Net cash used in investing activities (126,693) (5,820)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Stock-based compensation tax withholdings (7,385) (8,182)
Purchase of company stock, and related excise taxes (100,222) (40,050)
Repayments of debt principal (1,628) (1,500)
Other financing activities 1,949 0
Net cash used in financing activities (107,286) (49,732)
NET DECREASE IN CASH AND CASH EQUIVALENTS (241,193) (124,336)
Cash and cash equivalents - beginning of the period 412,565 343,849
CASH AND CASH EQUIVALENTS - END OF PERIOD 171,372 219,513
Supplemental disclosure of cash flow information:    
Cash paid for interest 10,763 12,173
Cash paid for income taxes 833 2
Cash paid for operating leases $ 7,548 $ 7,085
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.25.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Treasury Stock
Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Equity, beginning balance at Dec. 31, 2023 $ 1,421,672 $ 0 $ 18 $ (255,107) $ 1,204,270 $ 457,513 $ 14,978
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings (8,182)       (8,182)    
Stock-based incentive compensation 9,605       9,605    
Purchase of company stock, and related tax effects (40,289)     (40,289)      
Net income 44,791         44,791  
Other comprehensive income (loss) 1,551           1,551
Equity, ending balance at Mar. 31, 2024 1,429,148 0 18 (295,396) 1,205,693 502,304 16,529
Equity, beginning balance at Dec. 31, 2024 1,404,238 0 18 (507,598) 1,231,435 669,336 11,047
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings (5,436)       (5,436)    
Stock-based incentive compensation 8,801       8,801    
Purchase of company stock, and related tax effects (101,113)     (101,113)      
Net income 46,742         46,742  
Other comprehensive income (loss) (2,398)           (2,398)
Equity, ending balance at Mar. 31, 2025 $ 1,350,834 $ 0 $ 18 $ (608,711) $ 1,234,800 $ 716,078 $ 8,649
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.1
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
Corporate Organization and Business — Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 91 full service pharmacies, including 77 with ambulatory infusion suites. Additionally, the Company has 99 stand-alone ambulatory infusion suites, including 16 with advanced practitioner capabilities. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company’s stock is listed on the Nasdaq Global Select Market as of March 31, 2025.
Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2024 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.
Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2025, cash equivalents consisted of money market funds.
Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $33.9 million and $54.4 million as of March 31, 2025 and December 31, 2024, respectively.
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2025 and December 31, 2024, the balance of the investments was $26.2 million and $24.5 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.7 million and $1.1 million for the three months ended March 31, 2025 and 2024, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million. See Note 16, Related-Party Transactions, for discussion of related-party transactions with these investees.
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% and 14% for the three months ended March 31, 2025 and 2024, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.
For the three months ended March 31, 2025 and 2024, approximately 12% of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of March 31, 2025 and December 31, 2024, approximately 11% of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the three months ended March 31, 2025 and 2024, approximately 66% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS
 3 Months Ended
Mar. 31, 2025
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
BUSINESS COMBINATIONS BUSINESS COMBINATIONS
Intramed Plus, Inc. — On January 24, 2025, pursuant to the securities purchase agreement dated November 27, 2024, the Company completed the acquisition of 100% of the equity interests in Intramed Plus, Inc. (“Intramed Plus”) for a purchase price, net of cash acquired, of $117.3 million.
The allocation of the purchase price of Intramed Plus was accounted for as a business combination in accordance with ASC Topic 805, Business Combinations, with the total purchase price being allocated to the assets and liabilities acquired based on the relative fair value of each asset and liability. The following is a preliminary estimate of the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2025, which remains open for accounts receivable, accounts payable and intangible assets (in thousands):
Amount
Accounts receivable, net$10,128 
Referral sources (1)36,800 
Trademarks/names (1)8,300 
Inventory2,693 
Other assets4,831 
Accounts payable and other liabilities(11,114)
Fair value identifiable assets and liabilities51,638 
Goodwill (2)65,684 
Cash acquired2,968 
Purchase price120,290 
Less: cash acquired (2,968)
Purchase price, net of cash acquired$117,322 
(1) Referral sources and trademarks/names have been assigned a useful life of 15 years.
(2) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2025 and 2024 (in thousands):
Three Months Ended March 31,
20252024
Commercial payers$1,144,932 $988,043 
Government payers160,518 138,310 
Patients27,522 19,699 
Net revenue$1,332,972 $1,146,052 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2025
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
During the three months ended March 31, 2025 and 2024, the Company recorded tax expense of $16.8 million and $12.2 million, respectively, which represents an effective tax rate of 26.5% and 21.4%, respectively. The variance in the Company’s effective tax rate of 26.5% for the three months ended March 31, 2025, compared to the federal statutory rate of 21.0%, is primarily attributable to the difference between federal and state tax rates, and various non-deductible expenses. The variance in the Company’s effective tax rate of 21.4% for the three months ended March 31, 2024, compared to the federal statutory rate of 21.0%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the three months ended March 31, 2024, the Company released $2.2 million of state valuation allowance.
The Company maintains a valuation allowance of $3.3 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.
The Company’s tax expense of $16.8 million and $12.2 million for the three months ended March 31, 2025 and 2024, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.
The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (“Code”) Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March 31, 2025 and 2024 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Three Months Ended March 31,
20252024
Stock option awards702,287 880,815 
Restricted stock awards604,589 279,144 
Performance stock unit awards171,854 149,561 
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended March 31,
20252024
Numerator:
Net income$46,742 $44,791 
Denominator:
Weighted average number of common shares outstanding165,460 173,928 
Earnings per common share:
Earnings per common share, basic$0.28 $0.26 
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended March 31,
 20252024
Numerator:
Net income$46,742 $44,791 
Denominator:
Weighted average number of common shares outstanding165,460 173,928 
Effect of dilutive securities1,344 1,696 
Weighted average number of common shares outstanding, diluted166,804 175,624 
Earnings per common share:
Earnings per common share, diluted$0.28 $0.26 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES
 3 Months Ended
Mar. 31, 2025
Leases [Abstract]  
LEASES LEASES
During the three months ended March 31, 2025 and 2024, the Company incurred operating lease expenses of $8.2 million and $7.9 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2025 and December 31, 2024, the weighted-average remaining lease term was 6.6 years and 6.5 years, respectively, and the weighted-average discount rate was 6.77% and 6.56%, respectively.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$21,946 
202627,537 
202722,446 
202815,840 
202911,233 
Thereafter43,576 
Total lease payments142,578 
Less: interest(30,290)
Present value of lease liabilities$112,288 
During the three months ended March 31, 2025 and 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flows of $10.8 million and $11.3 million, respectively, related to increases in the operating lease right-of-use assets and operating lease liabilities. As of March 31, 2025, the Company did not have any significant operating or financing leases that had not yet commenced.
LEASES LEASES
During the three months ended March 31, 2025 and 2024, the Company incurred operating lease expenses of $8.2 million and $7.9 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2025 and December 31, 2024, the weighted-average remaining lease term was 6.6 years and 6.5 years, respectively, and the weighted-average discount rate was 6.77% and 6.56%, respectively.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$21,946 
202627,537 
202722,446 
202815,840 
202911,233 
Thereafter43,576 
Total lease payments142,578 
Less: interest(30,290)
Present value of lease liabilities$112,288 
During the three months ended March 31, 2025 and 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flows of $10.8 million and $11.3 million, respectively, related to increases in the operating lease right-of-use assets and operating lease liabilities. As of March 31, 2025, the Company did not have any significant operating or financing leases that had not yet commenced.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.25.1
PROPERTY AND EQUIPMENT
 3 Months Ended
Mar. 31, 2025
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
Property and equipment was as follows as of March 31, 2025 and December 31, 2024 (in thousands):
March 31, 2025December 31, 2024
Infusion pumps$38,623 $37,659 
Equipment, furniture and other21,222 24,055 
Leasehold improvements117,828 116,675 
Computer software, purchased and internally developed48,365 46,532 
Assets under development25,376 22,990 
251,414 247,911 
Less: accumulated depreciation(120,150)(120,544)
Property and equipment, net$131,264 $127,367 
Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2025 and 2024 (in thousands):
Three Months Ended March 31,
20252024
Depreciation expense in cost of revenue$627 $576 
Depreciation expense in operating expenses6,649 6,120 
Total depreciation expense$7,276 $6,696 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill consist of the following for the three months ended March 31, 2025 (in thousands):
Amount
Balance at December 31, 2024$1,540,246 
Acquisitions65,684 
Balance at March 31, 2025$1,605,930 
The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2025 and December 31, 2024 (in thousands):
March 31, 2025December 31, 2024
Gross intangible assets:
Referral sources$551,188 $514,388 
Trademarks/names47,436 39,136 
Other amortizable intangible assets985 985 
Total gross intangible assets599,609 554,509 
Accumulated amortization:
Referral sources(238,602)(230,371)
Trademarks/names(23,416)(22,599)
Other amortizable intangible assets(578)(529)
Total accumulated amortization(262,596)(253,499)
Total intangible assets, net$337,013 $301,010 
Amortization expense for intangible assets was $9.1 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.1
INDEBTEDNESS
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
INDEBTEDNESS INDEBTEDNESS
Long-term debt consisted of the following as of March 31, 2025 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan629,988 (5,194)(7,087)617,707 
Senior Notes500,000 — (7,035)492,965 
$1,129,988 $(5,194)$(14,122)1,110,672 
Less: current portion(6,512)
Total long-term debt$1,104,160 
Long-term debt consisted of the following as of December 31, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan631,617 (5,537)(7,555)618,525 
Senior Notes500,000 — (7,372)492,628 
$1,131,617 $(5,537)$(14,927)1,111,153 
Less: current portion(6,512)
Total long-term debt$1,104,641 
The interest rate on the First Lien Term Loan was 6.57% and 6.82% as of March 31, 2025 and December 31, 2024, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 6.58% and 8.20% for the three months ended March 31, 2025 and 2024, respectively. The First Lien Term Loan matures on October 27, 2028.
The interest rate on the Senior Notes was 4.375% as of March 31, 2025 and December 31, 2024. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three months ended March 31, 2025 and 2024. The Senior Notes mature on October 31, 2029.
As of March 31, 2025, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans.
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$4,884 
20266,512 
20276,512 
2028612,080 
2029500,000 
Total$1,129,988 
During the three months ended March 31, 2025 and 2024, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 11, Derivative Instruments, for further discussion.
The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2025 (in thousands):
Financial Instrument
Carrying Value as of March 31, 2025
Markets for Identical Item (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan$617,707 $— $631,563 $— 
Senior Notes492,965 — 463,750 — 
Total debt instruments$1,110,672 $— $1,095,313 $— 
See Note 12, Fair Value Measurements, for further discussion.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS
 3 Months Ended
Mar. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS DERIVATIVE INSTRUMENTS
The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.
In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a five-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.
The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionMarch 31, 2025December 31, 2024
Interest rate cap designated as cash flow hedgePrepaid expenses and other current assets$7,515 $8,034 
Interest rate cap designated as cash flow hedgeOther noncurrent assets4,018 6,680 
Total derivative assets$11,533 $14,714 
The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the hedging instrument is recognized in net income through interest expense.
The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):
Three Months Ended March 31,
Derivative20252024
Interest rate cap designated as cash flow hedge$(3,181)$2,005 
The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):
Three Months Ended March 31,
DerivativeIncome Statement Caption20252024
Interest rate cap designated as cash flow hedgeInterest expense, net$2,191 $2,980 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASURMENTS
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:
•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).
There were no other material assets or liabilities measured at fair value at March 31, 2025 and December 31, 2024.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.
The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.
However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED INCENTIVE COMPENSATION
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED INCENTIVE COMPENSATION STOCK-BASED INCENTIVE COMPENSATION
Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by stockholders on May 3, 2018 and amended and restated on May 19, 2021 and May 15, 2024, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. As of May 2021, a total of 9,101,734 shares of common stock were authorized for issuance under the 2018 Plan. In May 2024, an additional 4,000,000 shares were authorized for issuance under the 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March 31, 2025 and 2024. During the three months ended March 31, 2025 and 2024, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $8.8 million and $9.6 million, respectively.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
Warrants — As of March 31, 2025 and December 31, 2024, the Company has warrants outstanding which entitle holders to purchase an immaterial number of shares of common stock.
Share Repurchase Program — The Company’s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.
During the three months ended March 31, 2025 and 2024, the Company purchased 3,046,215 and 1,251,739 shares of common stock for an average share price of $32.83 and $31.96, totaling $100.0 million and $40.0 million, respectively. All repurchased shares became treasury stock. As of March 31, 2025, the Company is authorized to repurchase up to a remaining $400.0 million of common stock of the Company.
Shares Outstanding — The following table shows the Company’s changes in shares of common stock for the three months ended March 31, 2025 and 2024 (in thousands):
20252024
Balance, beginning of the year166,261 174,576 
Equity award issuances529 492 
Share repurchases(3,046)(1,252)
Balance March 31,163,744 173,816 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED-PARTY TRANSACTIONS
 3 Months Ended
Mar. 31, 2025
Related Party Transactions [Abstract]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONS
Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.8 million and $1.5 million for the three months ended March 31, 2025 and 2024, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million.
The Company had amounts due to its joint ventures of $2.5 million and $1.4 million as of March 31, 2025 and December 31, 2024, respectively. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company has adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures and has revised prior year disclosures to conform with the current year presentation. The Company operates as a single reportable segment, infusion services. Infusion services derives revenue through the clinical management of infusion therapy, nursing support and care coordination in order to provide solutions to complex patient conditions in the home or other nonhospital settings. The Company’s infusion services segment activities are managed on a consolidated basis and therapies are distributed and administered in a similar manner.
Operating segments have been identified based on the financial information utilized by the Company’s Chief Executive Officer, the chief operating decision maker (“CODM”). The CODM uses net income as a measure of profitability to assess segment performance and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.
The following table reflects results of operations of the Company’s reportable segment (in thousands):
Three Months Ended March 31,
20252024
Infusion services net revenue$1,311,181 $1,125,662 
Other revenue (1)21,791 20,390 
Total Option Care Health revenue1,332,972 1,146,052 
(Expense) Income:
Cost of net revenues - drugs(933,068)(777,260)
Salaries, benefits, and other employee expense(205,692)(191,815)
Other segment items (2)(99,278)(93,219)
Depreciation and amortization expense(15,746)(14,728)
Interest expense, net(13,231)(13,202)
Equity in earnings of joint ventures1,729 1,125 
Other, net(4,130)2 
Income tax expense(16,814)(12,164)
Net Income$46,742 $44,791 
(1) Represents business activities related to other miscellaneous revenue streams.
(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net income $ 46,742 $ 44,791
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2024 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.
Principles of Consolidation
Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
Cash and Cash Equivalents
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2025, cash equivalents consisted of money market funds.
Equity Method Investments
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2025 and December 31, 2024, the balance of the investments was $26.2 million and $24.5 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.7 million and $1.1 million for the three months ended March 31, 2025 and 2024, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million. See Note 16, Related-Party Transactions, for discussion of related-party transactions with these investees.
Concentrations of Business Risk
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% and 14% for the three months ended March 31, 2025 and 2024, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.
For the three months ended March 31, 2025 and 2024, approximately 12% of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of March 31, 2025 and December 31, 2024, approximately 11% of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the three months ended March 31, 2025 and 2024, approximately 66% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results.
Fair Value Measurements FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:
•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).
There were no other material assets or liabilities measured at fair value at March 31, 2025 and December 31, 2024.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS (Tables)
 3 Months Ended
Mar. 31, 2025
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Acquired Identifiable Assets and Assumed Liabilities The following is a preliminary estimate of the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2025, which remains open for accounts receivable, accounts payable and intangible assets (in thousands):
Amount
Accounts receivable, net$10,128 
Referral sources (1)36,800 
Trademarks/names (1)8,300 
Inventory2,693 
Other assets4,831 
Accounts payable and other liabilities(11,114)
Fair value identifiable assets and liabilities51,638 
Goodwill (2)65,684 
Cash acquired2,968 
Purchase price120,290 
Less: cash acquired (2,968)
Purchase price, net of cash acquired$117,322 
(1) Referral sources and trademarks/names have been assigned a useful life of 15 years.
(2) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE (Tables)
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Net Revenue Earned by Category of Payer
The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2025 and 2024 (in thousands):
Three Months Ended March 31,
20252024
Commercial payers$1,144,932 $988,043 
Government payers160,518 138,310 
Patients27,522 19,699 
Net revenue$1,332,972 $1,146,052 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Three Months Ended March 31,
20252024
Stock option awards702,287 880,815 
Restricted stock awards604,589 279,144 
Performance stock unit awards171,854 149,561 
Schedule of Basic and Diluted Earnings Per Share
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended March 31,
20252024
Numerator:
Net income$46,742 $44,791 
Denominator:
Weighted average number of common shares outstanding165,460 173,928 
Earnings per common share:
Earnings per common share, basic$0.28 $0.26 
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended March 31,
 20252024
Numerator:
Net income$46,742 $44,791 
Denominator:
Weighted average number of common shares outstanding165,460 173,928 
Effect of dilutive securities1,344 1,696 
Weighted average number of common shares outstanding, diluted166,804 175,624 
Earnings per common share:
Earnings per common share, diluted$0.28 $0.26 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES (Tables)
 3 Months Ended
Mar. 31, 2025
Leases [Abstract]  
Schedule of Maturities of Lease Liabilities, Operating
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$21,946 
202627,537 
202722,446 
202815,840 
202911,233 
Thereafter43,576 
Total lease payments142,578 
Less: interest(30,290)
Present value of lease liabilities$112,288 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.1
PROPERTY AND EQUIPMENT (Tables)
 3 Months Ended
Mar. 31, 2025
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment was as follows as of March 31, 2025 and December 31, 2024 (in thousands):
March 31, 2025December 31, 2024
Infusion pumps$38,623 $37,659 
Equipment, furniture and other21,222 24,055 
Leasehold improvements117,828 116,675 
Computer software, purchased and internally developed48,365 46,532 
Assets under development25,376 22,990 
251,414 247,911 
Less: accumulated depreciation(120,150)(120,544)
Property and equipment, net$131,264 $127,367 
The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2025 and 2024 (in thousands):
Three Months Ended March 31,
20252024
Depreciation expense in cost of revenue$627 $576 
Depreciation expense in operating expenses6,649 6,120 
Total depreciation expense$7,276 $6,696 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
Changes in the carrying amount of goodwill consist of the following for the three months ended March 31, 2025 (in thousands):
Amount
Balance at December 31, 2024$1,540,246 
Acquisitions65,684 
Balance at March 31, 2025$1,605,930 
Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets
The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2025 and December 31, 2024 (in thousands):
March 31, 2025December 31, 2024
Gross intangible assets:
Referral sources$551,188 $514,388 
Trademarks/names47,436 39,136 
Other amortizable intangible assets985 985 
Total gross intangible assets599,609 554,509 
Accumulated amortization:
Referral sources(238,602)(230,371)
Trademarks/names(23,416)(22,599)
Other amortizable intangible assets(578)(529)
Total accumulated amortization(262,596)(253,499)
Total intangible assets, net$337,013 $301,010 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.1
INDEBTEDNESS (Tables)
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
Schedule of Debt
Long-term debt consisted of the following as of March 31, 2025 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan629,988 (5,194)(7,087)617,707 
Senior Notes500,000 — (7,035)492,965 
$1,129,988 $(5,194)$(14,122)1,110,672 
Less: current portion(6,512)
Total long-term debt$1,104,160 
Long-term debt consisted of the following as of December 31, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan631,617 (5,537)(7,555)618,525 
Senior Notes500,000 — (7,372)492,628 
$1,131,617 $(5,537)$(14,927)1,111,153 
Less: current portion(6,512)
Total long-term debt$1,104,641 
Schedule of Long-term Debt Maturities
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$4,884 
20266,512 
20276,512 
2028612,080 
2029500,000 
Total$1,129,988 
Schedule of Estimated Fair Values of Debt Obligations
The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2025 (in thousands):
Financial Instrument
Carrying Value as of March 31, 2025
Markets for Identical Item (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan$617,707 $— $631,563 $— 
Senior Notes492,965 — 463,750 — 
Total debt instruments$1,110,672 $— $1,095,313 $— 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Amount and Location of Derivatives in the Balance Sheet
The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionMarch 31, 2025December 31, 2024
Interest rate cap designated as cash flow hedgePrepaid expenses and other current assets$7,515 $8,034 
Interest rate cap designated as cash flow hedgeOther noncurrent assets4,018 6,680 
Total derivative assets$11,533 $14,714 
Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)
The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):
Three Months Ended March 31,
Derivative20252024
Interest rate cap designated as cash flow hedge$(3,181)$2,005 
The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):
Three Months Ended March 31,
DerivativeIncome Statement Caption20252024
Interest rate cap designated as cash flow hedgeInterest expense, net$2,191 $2,980 
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Schedule of Common Stock Outstanding Roll Forward The following table shows the Company’s changes in shares of common stock for the three months ended March 31, 2025 and 2024 (in thousands):
20252024
Balance, beginning of the year166,261 174,576 
Equity award issuances529 492 
Share repurchases(3,046)(1,252)
Balance March 31,163,744 173,816 
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table reflects results of operations of the Company’s reportable segment (in thousands):
Three Months Ended March 31,
20252024
Infusion services net revenue$1,311,181 $1,125,662 
Other revenue (1)21,791 20,390 
Total Option Care Health revenue1,332,972 1,146,052 
(Expense) Income:
Cost of net revenues - drugs(933,068)(777,260)
Salaries, benefits, and other employee expense(205,692)(191,815)
Other segment items (2)(99,278)(93,219)
Depreciation and amortization expense(15,746)(14,728)
Interest expense, net(13,231)(13,202)
Equity in earnings of joint ventures1,729 1,125 
Other, net(4,130)2 
Income tax expense(16,814)(12,164)
Net Income$46,742 $44,791 
(1) Represents business activities related to other miscellaneous revenue streams.
(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.25.1
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)
 3 Months Ended
Mar. 31, 2025
pharmacy
suite
segment
Business Acquisition [Line Items]  
Number of service locations | pharmacy 91
Number of service locations, including ambulatory infusion suites | pharmacy 77
Number of infusion sites | suite 99
Number of infusion sites, including advances practitioner capabilities | suite 16
Number of operating segments | segment 1
Legacy Health Systems  
Business Acquisition [Line Items]  
Ownership interest 50.00%
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Concentration Risk [Line Items]      
Rebate receivable $ 33,900   $ 54,400
Investments in equity-method investees 26,200   $ 24,500
Equity in earnings of joint ventures 1,729 $ 1,125  
Distributions received from the investees $ 0 750  
Joint Venture      
Concentration Risk [Line Items]      
Distributions received from the investees   $ 800  
Revenue from Contract with Customer Benchmark | Company's Largest Payer | Largest Payer      
Concentration Risk [Line Items]      
Concentration ​risk 15.00% 14.00%  
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs      
Concentration Risk [Line Items]      
Concentration ​risk 12.00% 12.00%  
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs      
Concentration Risk [Line Items]      
Concentration ​risk 11.00%   11.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors      
Concentration Risk [Line Items]      
Concentration ​risk 66.00% 66.00%  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 24, 2025
Mar. 31, 2025
Mar. 31, 2024
Business Acquisition [Line Items]      
Purchase price, net of cash acquired   $ 117,322 $ 0
Intramed Plus, Inc      
Business Acquisition [Line Items]      
Percentage of the combined company held 100.00%    
Purchase price, net of cash acquired $ 117,322    
Intramed Plus, Inc | Referral sources (1)      
Business Acquisition [Line Items]      
Intangible assets useful life 15 years    
Intramed Plus, Inc | Trademarks/names      
Business Acquisition [Line Items]      
Intangible assets useful life 15 years    
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS - Preliminary Estimate of the Allocation Consideration Transferred (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 24, 2025
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Business Acquisition [Line Items]        
Goodwill (2)   $ 1,605,930   $ 1,540,246
Purchase price, net of cash acquired   $ 117,322 $ 0  
Intramed Plus, Inc        
Business Acquisition [Line Items]        
Accounts receivable, net $ 10,128      
Inventory 2,693      
Other assets 4,831      
Accounts payable and other liabilities (11,114)      
Fair value identifiable assets and liabilities 51,638      
Goodwill (2) 65,684      
Cash acquired 2,968      
Purchase price 120,290      
Less: cash acquired (2,968)      
Purchase price, net of cash acquired 117,322      
Intramed Plus, Inc | Referral sources (1)        
Business Acquisition [Line Items]        
Finite-lived intangible assets 36,800      
Intramed Plus, Inc | Trademarks/names        
Business Acquisition [Line Items]        
Finite-lived intangible assets $ 8,300      
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Net revenue $ 1,332,972 $ 1,146,052
Commercial payers    
Disaggregation of Revenue [Line Items]    
Net revenue 1,144,932 988,043
Government payers    
Disaggregation of Revenue [Line Items]    
Net revenue 160,518 138,310
Patients    
Disaggregation of Revenue [Line Items]    
Net revenue $ 27,522 $ 19,699
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Tax Examination [Line Items]    
Income tax expense $ 16,814 $ 12,164
Effective tax rate 26.50% 21.40%
State jurisdiction    
Income Tax Examination [Line Items]    
Release of valuation allowance   $ 2,200
Valuation allowance $ 3,300  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Stock option awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (in shares) 702,287 880,815
Restricted stock awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (in shares) 604,589 279,144
Performance stock unit awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (in shares) 171,854 149,561
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.25.1
EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Numerator:    
Net income $ 46,742 $ 44,791
Denominator:    
Weighted average number of common shares outstanding (in shares) 165,460 173,928
Effect of dilutive securities (in shares) 1,344 1,696
Weighted average number of common shares outstanding, diluted (in shares) 166,804 175,624
Earnings per common share, basic    
Earnings per common share, basic (in dollars per share) $ 0.28 $ 0.26
Earnings per common share, diluted    
Earnings per common share, diluted (in dollars per share) $ 0.28 $ 0.26
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Leases [Abstract]      
Operating lease cost $ 8.2 $ 7.9  
Weighted-average remaining lease term, operating leases 6 years 7 months 6 days   6 years 6 months
Weighted-average discount rate, operating leases 6.77%   6.56%
Increase in operating lease right-of-use asset and lease liabilities $ 10.8 $ 11.3  
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES - Maturities of Lease Liabilities (Details)
$ in Thousands
Mar. 31, 2025
USD ($)
Minimum Payments  
2025 $ 21,946
2026 27,537
2027 22,446
2028 15,840
2029 11,233
Thereafter 43,576
Total lease payments 142,578
Less: interest (30,290)
Present value of lease liabilities $ 112,288
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.25.1
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 251,414   $ 247,911
Less: accumulated depreciation (120,150)   (120,544)
Property and equipment, net 131,264   127,367
Total depreciation expense 7,276 $ 6,696  
Depreciation expense in cost of revenue      
Property, Plant and Equipment [Line Items]      
Total depreciation expense 627 576  
Depreciation expense in operating expenses      
Property, Plant and Equipment [Line Items]      
Total depreciation expense 6,649 $ 6,120  
Infusion pumps      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 38,623   37,659
Equipment, furniture and other      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 21,222   24,055
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 117,828   116,675
Computer software, purchased and internally developed      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 48,365   46,532
Assets under development      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 25,376   $ 22,990
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
Goodwill [Roll Forward]  
Goodwill - net book value, begging of period $ 1,540,246
Acquisitions 65,684
Goodwill - net book value, end of period $ 1,605,930
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets $ 599,609 $ 554,509
Total accumulated amortization (262,596) (253,499)
Total intangible assets, net 337,013 301,010
Referral sources    
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets 551,188 514,388
Total accumulated amortization (238,602) (230,371)
Trademarks/names    
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets 47,436 39,136
Total accumulated amortization (23,416) (22,599)
Other amortizable intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets 985 985
Total accumulated amortization $ (578) $ (529)
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense for intangible assets $ 9.1 $ 8.6
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.25.1
INDEBTEDNESS - Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Instrument [Line Items]    
Principal Amount $ 1,129,988 $ 1,131,617
Discount (5,194) (5,537)
Debt Issuance Costs (14,122) (14,927)
Net Balance 1,110,672 1,111,153
Less: current portion (6,512) (6,512)
Total long-term debt 1,104,160 1,104,641
Senior Notes | First Lien Term Loan    
Debt Instrument [Line Items]    
Principal Amount 629,988 631,617
Discount (5,194) (5,537)
Debt Issuance Costs (7,087) (7,555)
Net Balance 617,707 618,525
Senior Notes | Senior Notes    
Debt Instrument [Line Items]    
Principal Amount 500,000 500,000
Discount 0 0
Debt Issuance Costs (7,035) (7,372)
Net Balance 492,965 492,628
Senior Notes | Revolver Facility    
Debt Instrument [Line Items]    
Principal Amount 0 0
Discount 0 0
Debt Issuance Costs 0 0
Net Balance $ 0 $ 0
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.25.1
INDEBTEDNESS - Additional Information (Details) - Senior Notes - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Credit Agreements, Entered Into 2019 | First Lien Term Loan      
Debt Instrument [Line Items]      
Effective rate on term loans at end of period 6.57%   6.82%
Weighted average interest rate paid on term loans during period 6.58% 8.20%  
Credit Agreements, Entered Into 2019 | Second Lien Term Loan      
Debt Instrument [Line Items]      
Effective rate on term loans at end of period 4.375%   4.375%
Weighted average interest rate paid on term loans during period 4.375% 4.375%  
Revolver Facility | Credit Agreements, Entered Into 2019      
Debt Instrument [Line Items]      
Undrawn letters of credit issued and outstanding $ 4.1    
Revolver Facility | Second Lien Credit Agreement      
Debt Instrument [Line Items]      
Available borrowing capacity $ 395.9    
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.25.1
INDEBTEDNESS - Long Term Debt Maturities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Disclosure [Abstract]    
2025 $ 4,884  
2026 6,512  
2027 6,512  
2028 612,080  
2029 500,000  
Total $ 1,129,988 $ 1,131,617
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.25.1
INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)
$ in Thousands
Mar. 31, 2025
USD ($)
Debt Instrument [Line Items]  
Total debt instruments $ 1,110,672
Markets for Identical Item (Level 1)  
Debt Instrument [Line Items]  
Total debt instruments 0
Significant Other Observable Inputs (Level 2)  
Debt Instrument [Line Items]  
Total debt instruments 1,095,313
Significant Unobservable Inputs (Level 3)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes  
Debt Instrument [Line Items]  
Total debt instruments 492,965
Senior Notes | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 617,707
Senior Notes | Markets for Identical Item (Level 1)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Markets for Identical Item (Level 1) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Significant Other Observable Inputs (Level 2)  
Debt Instrument [Line Items]  
Total debt instruments 463,750
Senior Notes | Significant Other Observable Inputs (Level 2) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 631,563
Senior Notes | Significant Unobservable Inputs (Level 3)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Significant Unobservable Inputs (Level 3) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments $ 0
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS - Additional Information (Details) - Interest rate cap designated as cash flow hedge - First Lien Term Loan - Designated as Hedging Instrument - Senior Notes
 1 Months Ended
Oct. 31, 2021
USD ($)
Derivative [Line Items]  
Notional amount of derivative $ 300,000,000
Derivative, term of contract 5 years
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Derivative [Line Items]    
Total derivative assets $ 11,533 $ 14,714
Designated as Hedging Instrument | Prepaid expenses and other current assets | Interest rate cap designated as cash flow hedge    
Derivative [Line Items]    
Total derivative assets 7,515 8,034
Designated as Hedging Instrument | Other noncurrent assets | Interest rate cap designated as cash flow hedge    
Derivative [Line Items]    
Total derivative assets $ 4,018 $ 6,680
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.25.1
DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - Interest rate cap designated as cash flow hedge - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Derivative [Line Items]    
Interest rate cap designated as cash flow hedge $ (3,181) $ 2,005
Interest expense, net    
Derivative [Line Items]    
Interest rate cap designated as cash flow hedge $ 2,191 $ 2,980
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED INCENTIVE COMPENSATION (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
May 31, 2024
Mar. 31, 2025
Mar. 31, 2024
May 31, 2021
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Number of shares authorized (in shares) 13,101,734      
2018 Plan        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Number of shares authorized (in shares)       9,101,734
Number of additional shares authorized (in shares) 4,000,000      
HC I Incentive Units | 2018 Plan        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Share-based compensation expense   $ 8.8 $ 9.6  
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS' EQUITY (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 06, 2023
Class of Warrant or Right [Line Items]      
Treasury stock, shares, acquired (in shares) 3,046,215 1,251,739  
Treasury stock acquired, average cost per share (in dollars per share) $ 32.83 $ 31.96  
Shares repurchased $ 100.0 $ 40.0  
Stock repurchase program, authorized amount $ 400.0    
Common Stock      
Class of Warrant or Right [Line Items]      
Number of shares authorized to be repurchased (in shares)     500,000,000.0
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) - shares
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of the year 166,261,112  
Balance, end of the period 163,744,493  
Common Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of the year 166,261,000 174,576,000
Equity award issuances 529,000 492,000
Share repurchases (3,046,000) (1,252,000)
Balance, end of the period 163,744,000 173,816,000
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED-PARTY TRANSACTIONS (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Related Party Transaction [Line Items]      
Distributions received from the investees $ 0 $ 750  
Joint Venture      
Related Party Transaction [Line Items]      
Management fee income 1,800 1,500  
Distributions received from the investees   $ 800  
Due to joint ventures $ 2,500   $ 1,400
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Total Option Care Health revenue $ 1,332,972 $ 1,146,052
Income (Expense) [Abstract]    
Depreciation and amortization expense (15,746) (14,728)
Interest expense, net (13,231) (13,202)
Equity in earnings of joint ventures 1,729 1,125
Other, net (4,130) 2
Income tax expense (16,814) (12,164)
NET INCOME 46,742 44,791
Reportable Segment    
Segment Reporting Information [Line Items]    
Infusion services net revenue 1,311,181 1,125,662
Other revenue 21,791 20,390
Total Option Care Health revenue 1,332,972 1,146,052
Income (Expense) [Abstract]    
Cost of net revenues - drugs (933,068) (777,260)
Salaries, benefits, and other employee expense (205,692) (191,815)
Other segment items (99,278) (93,219)
Depreciation and amortization expense (15,746) (14,728)
Interest expense, net (13,231) (13,202)
Equity in earnings of joint ventures 1,729 1,125
Other, net (4,130) 2
Income tax expense (16,814) (12,164)
NET INCOME $ 46,742 $ 44,791
EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 138 249 1 false 55 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.bioscrip.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 4 false false R5.htm 9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Statements 5 false false R6.htm 9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 7 false false R8.htm 9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Sheet http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Notes 8 false false R9.htm 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 9952159 - Disclosure - BUSINESS COMBINATIONS Sheet http://www.bioscrip.com/role/BUSINESSCOMBINATIONS BUSINESS COMBINATIONS Notes 10 false false R11.htm 9952160 - Disclosure - REVENUE Sheet http://www.bioscrip.com/role/REVENUE REVENUE Notes 11 false false R12.htm 9952161 - Disclosure - INCOME TAXES Sheet http://www.bioscrip.com/role/INCOMETAXES INCOME TAXES Notes 12 false false R13.htm 9952162 - Disclosure - EARNINGS PER SHARE Sheet http://www.bioscrip.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 13 false false R14.htm 9952163 - Disclosure - LEASES Sheet http://www.bioscrip.com/role/LEASES LEASES Notes 14 false false R15.htm 9952164 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 15 false false R16.htm 9952165 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 16 false false R17.htm 9952166 - Disclosure - INDEBTEDNESS Sheet http://www.bioscrip.com/role/INDEBTEDNESS INDEBTEDNESS Notes 17 false false R18.htm 9952167 - Disclosure - DERIVATIVE INSTRUMENTS Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS DERIVATIVE INSTRUMENTS Notes 18 false false R19.htm 9952168 - Disclosure - FAIR VALUE MEASURMENTS Sheet http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS FAIR VALUE MEASURMENTS Notes 19 false false R20.htm 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 9952170 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION STOCK-BASED INCENTIVE COMPENSATION Notes 21 false false R22.htm 9952171 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 22 false false R23.htm 9952172 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS RELATED-PARTY TRANSACTIONS Notes 23 false false R24.htm 9952173 - Disclosure - SEGMENT REPORTING Sheet http://www.bioscrip.com/role/SEGMENTREPORTING SEGMENT REPORTING Notes 24 false false R25.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 27 false false R28.htm 9955512 - Disclosure - BUSINESS COMBINATIONS (Tables) Sheet http://www.bioscrip.com/role/BUSINESSCOMBINATIONSTables BUSINESS COMBINATIONS (Tables) Tables http://www.bioscrip.com/role/BUSINESSCOMBINATIONS 28 false false R29.htm 9955513 - Disclosure - REVENUE (Tables) Sheet http://www.bioscrip.com/role/REVENUETables REVENUE (Tables) Tables http://www.bioscrip.com/role/REVENUE 29 false false R30.htm 9955514 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.bioscrip.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.bioscrip.com/role/EARNINGSPERSHARE 30 false false R31.htm 9955515 - Disclosure - LEASES (Tables) Sheet http://www.bioscrip.com/role/LEASESTables LEASES (Tables) Tables http://www.bioscrip.com/role/LEASES 31 false false R32.htm 9955516 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT 32 false false R33.htm 9955517 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 33 false false R34.htm 9955518 - Disclosure - INDEBTEDNESS (Tables) Sheet http://www.bioscrip.com/role/INDEBTEDNESSTables INDEBTEDNESS (Tables) Tables http://www.bioscrip.com/role/INDEBTEDNESS 34 false false R35.htm 9955519 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables DERIVATIVE INSTRUMENTS (Tables) Tables http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS 35 false false R36.htm 9955520 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.bioscrip.com/role/STOCKHOLDERSEQUITY 36 false false R37.htm 9955521 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://www.bioscrip.com/role/SEGMENTREPORTINGTables SEGMENT REPORTING (Tables) Tables http://www.bioscrip.com/role/SEGMENTREPORTING 37 false false R38.htm 9955522 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) Sheet http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) Details http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS 38 false false R39.htm 9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 39 false false R40.htm 9955524 - Disclosure - BUSINESS COMBINATIONS - Additional Information (Details) Sheet http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails BUSINESS COMBINATIONS - Additional Information (Details) Details 40 false false R41.htm 9955525 - Disclosure - BUSINESS COMBINATIONS - Preliminary Estimate of the Allocation Consideration Transferred (Details) Sheet http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails BUSINESS COMBINATIONS - Preliminary Estimate of the Allocation Consideration Transferred (Details) Details 41 false false R42.htm 9955526 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details) Sheet http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails REVENUE - Net Revenue Earned by Category of Payer (Details) Details 42 false false R43.htm 9955527 - Disclosure - INCOME TAXES (Details) Sheet http://www.bioscrip.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.bioscrip.com/role/INCOMETAXES 43 false false R44.htm 9955528 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 44 false false R45.htm 9955529 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) Sheet http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) Details 45 false false R46.htm 9955530 - Disclosure - LEASES - Additional Information (Details) Sheet http://www.bioscrip.com/role/LEASESAdditionalInformationDetails LEASES - Additional Information (Details) Details 46 false false R47.htm 9955531 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) Sheet http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails LEASES - Maturities of Lease Liabilities (Details) Details 47 false false R48.htm 9955532 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables 48 false false R49.htm 9955533 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) Details 49 false false R50.htm 9955534 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) Details 50 false false R51.htm 9955535 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 51 false false R52.htm 9955536 - Disclosure - INDEBTEDNESS - Debt (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails INDEBTEDNESS - Debt (Details) Details 52 false false R53.htm 9955537 - Disclosure - INDEBTEDNESS - Additional Information (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails INDEBTEDNESS - Additional Information (Details) Details 53 false false R54.htm 9955538 - Disclosure - INDEBTEDNESS - Long Term Debt Maturities (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails INDEBTEDNESS - Long Term Debt Maturities (Details) Details 54 false false R55.htm 9955539 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) Details 55 false false R56.htm 9955540 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails DERIVATIVE INSTRUMENTS - Additional Information (Details) Details 56 false false R57.htm 9955541 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) Details 57 false false R58.htm 9955542 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) Details 58 false false R59.htm 9955543 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails STOCK-BASED INCENTIVE COMPENSATION (Details) Details http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION 59 false false R60.htm 9955544 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails STOCKHOLDERS' EQUITY (Details) Details http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables 60 false false R61.htm 9955545 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) Details 61 false false R62.htm 9955546 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED-PARTY TRANSACTIONS (Details) Details http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS 62 false false R63.htm 9955547 - Disclosure - SEGMENT REPORTING (Details) Sheet http://www.bioscrip.com/role/SEGMENTREPORTINGDetails SEGMENT REPORTING (Details) Details http://www.bioscrip.com/role/SEGMENTREPORTINGTables 63 false false All Reports Book All Reports bios-20250331.htm bios-20250331.xsd bios-20250331_cal.xml bios-20250331_def.xml bios-20250331_lab.xml bios-20250331_pre.xml bios-20250331_g1.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 82 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bios-20250331.htm": { "nsprefix": "bios", "nsuri": "http://www.bioscrip.com/20250331", "dts": { "inline": { "local": [ "bios-20250331.htm" ] }, "schema": { "local": [ "bios-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bios-20250331_cal.xml" ] }, "definitionLink": { "local": [ "bios-20250331_def.xml" ] }, "labelLink": { "local": [ "bios-20250331_lab.xml" ] }, "presentationLink": { "local": [ "bios-20250331_pre.xml" ] } }, "keyStandard": 235, "keyCustom": 14, "axisStandard": 25, "axisCustom": 0, "memberStandard": 34, "memberCustom": 21, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 138, "entityCount": 1, "segmentCount": 55, "elementCount": 532, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 515, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.bioscrip.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R5": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical", "longName": "9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R7": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS", "longName": "9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bioscrip.com/role/BUSINESSCOMBINATIONS", "longName": "9952159 - Disclosure - BUSINESS COMBINATIONS", "shortName": "BUSINESS COMBINATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bioscrip.com/role/REVENUE", "longName": "9952160 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bioscrip.com/role/INCOMETAXES", "longName": "9952161 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHARE", "longName": "9952162 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bioscrip.com/role/LEASES", "longName": "9952163 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT", "longName": "9952164 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "9952165 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bioscrip.com/role/INDEBTEDNESS", "longName": "9952166 - Disclosure - INDEBTEDNESS", "shortName": "INDEBTEDNESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS", "longName": "9952167 - Disclosure - DERIVATIVE INSTRUMENTS", "shortName": "DERIVATIVE INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS", "longName": "9952168 - Disclosure - FAIR VALUE MEASURMENTS", "shortName": "FAIR VALUE MEASURMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION", "longName": "9952170 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION", "shortName": "STOCK-BASED INCENTIVE COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY", "longName": "9952171 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS", "longName": "9952172 - Disclosure - RELATED-PARTY TRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bioscrip.com/role/SEGMENTREPORTING", "longName": "9952173 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSTables", "longName": "9955512 - Disclosure - BUSINESS COMBINATIONS (Tables)", "shortName": "BUSINESS COMBINATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bioscrip.com/role/REVENUETables", "longName": "9955513 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHARETables", "longName": "9955514 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bioscrip.com/role/LEASESTables", "longName": "9955515 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables", "longName": "9955516 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "longName": "9955517 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSTables", "longName": "9955518 - Disclosure - INDEBTEDNESS (Tables)", "shortName": "INDEBTEDNESS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables", "longName": "9955519 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables", "longName": "9955520 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bioscrip.com/role/SEGMENTREPORTINGTables", "longName": "9955521 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "longName": "9955522 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)", "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "bios:NumberOfServiceLocations", "unitRef": "pharmacy", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "bios:NumberOfServiceLocations", "unitRef": "pharmacy", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "longName": "9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "longName": "9955524 - Disclosure - BUSINESS COMBINATIONS - Additional Information (Details)", "shortName": "BUSINESS COMBINATIONS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R41": { "role": "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "longName": "9955525 - Disclosure - BUSINESS COMBINATIONS - Preliminary Estimate of the Allocation Consideration Transferred (Details)", "shortName": "BUSINESS COMBINATIONS - Preliminary Estimate of the Allocation Consideration Transferred (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R42": { "role": "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "longName": "9955526 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)", "shortName": "REVENUE - Net Revenue Earned by Category of Payer (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-56", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R43": { "role": "http://www.bioscrip.com/role/INCOMETAXESDetails", "longName": "9955527 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R44": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "longName": "9955528 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-64", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "longName": "9955529 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)", "shortName": "EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R46": { "role": "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails", "longName": "9955530 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "longName": "9955531 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)", "shortName": "LEASES - Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails", "longName": "9955532 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "shortName": "PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails", "longName": "9955533 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R50": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "longName": "9955534 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "longName": "9955535 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "longName": "9955536 - Disclosure - INDEBTEDNESS - Debt (Details)", "shortName": "INDEBTEDNESS - Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R53": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "longName": "9955537 - Disclosure - INDEBTEDNESS - Additional Information (Details)", "shortName": "INDEBTEDNESS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-96", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-96", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails", "longName": "9955538 - Disclosure - INDEBTEDNESS - Long Term Debt Maturities (Details)", "shortName": "INDEBTEDNESS - Long Term Debt Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "longName": "9955539 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)", "shortName": "INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "longName": "9955540 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-116", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "longName": "9955541 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails", "longName": "9955542 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-122", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails", "longName": "9955543 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-128", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-128", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "longName": "9955544 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "shortName": "STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "longName": "9955545 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details)", "shortName": "STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-25", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R62": { "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9955546 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)", "shortName": "RELATED-PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentDividendsOrDistributions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-134", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } }, "R63": { "role": "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "longName": "9955547 - Disclosure - SEGMENT REPORTING (Details)", "shortName": "SEGMENT REPORTING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-137", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20250331.htm", "unique": true } } }, "tag": { "bios_A2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "A2018PlanMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 Plan", "label": "2018 Plan [Member]", "documentation": "2018 Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r75", "r735" ] }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due to joint ventures", "label": "Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": [ "r133" ] }, "bios_AccountsReceivableBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "AccountsReceivableBenchmarkMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Benchmark", "label": "Accounts Receivable, Benchmark [Member]", "documentation": "Accounts Receivable, Benchmark" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r874" ] }, "bios_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r33", "r165", "r552" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r93", "r175", "r548", "r588", "r589" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r11", "r17", "r473", "r476", "r524", "r584", "r585", "r850", "r851", "r852", "r863", "r864", "r865", "r866" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r293", "r686" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r790" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r88" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r601", "r863", "r864", "r865", "r866", "r949", "r1007" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r803" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r803" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r803" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r803" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based incentive compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r45", "r46", "r396" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash used in operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r836" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r762", "r772", "r782", "r814" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r765", "r775", "r785", "r817" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r837" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r803" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r810" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r766", "r776", "r786", "r810", "r818", "r822", "r830" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r828" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r425", "r429" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r348", "r710", "r711", "r857", "r965" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r290", "r297", "r706" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r230" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AssetUnderConstructionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetUnderConstructionMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under development", "label": "Asset under Construction [Member]", "documentation": "Asset in process of being built." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r131", "r142", "r169", "r205", "r234", "r241", "r259", "r263", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r463", "r465", "r503", "r543", "r632", "r700", "r701", "r735", "r753", "r910", "r911", "r970" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r161", "r177", "r205", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r463", "r465", "r503", "r735", "r910", "r911", "r970" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r205", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r463", "r465", "r503", "r910", "r911", "r970" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "NONCURRENT ASSETS:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r825" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r826" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r821" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r821" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r821" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r821" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r821" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r821" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r824" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r823" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r822" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r822" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r309", "r974", "r975" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r59", "r62", "r309", "r974", "r975" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r459", "r723", "r724" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r47", "r49", "r291", "r292", "r293", "r294", "r295", "r459", "r723", "r724" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r459" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of the combined company held", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r48" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]", "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r0", "r1", "r10" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS COMBINATIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r125", "r460" ] }, "bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts payable and other liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable and Other Liabilities", "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable and Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r51" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair value identifiable assets and liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r51" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r74", "r112", "r113" ] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash acquired", "negatedTerseLabel": "Less: cash acquired", "label": "Cash Acquired from Acquisition", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r163", "r689" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r22" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents - beginning of the period", "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r109", "r201" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r109" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r801" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r798" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r796" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r172", "r173", "r174", "r236", "r357", "r358", "r359", "r361", "r364", "r369", "r371", "r592", "r593", "r594", "r595", "r712", "r840", "r858" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r43" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r802" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r802" ] }, "bios_CommercialCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "CommercialCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial payers", "label": "Commercial Customer [Member]", "documentation": "Commercial Customer [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r118", "r313", "r314", "r685", "r901", "r905" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r744", "r745", "r746", "r748", "r749", "r750", "r751", "r863", "r864", "r866", "r949", "r1005", "r1007" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r87" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r87", "r620" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r87" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "periodStartLabel": "Balance, beginning of the year", "periodEndLabel": "Balance, end of the period", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r87", "r620", "r638", "r1007", "r1008" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.0001 par value: 250,000,000 shares authorized, 184,376,321 shares issued and 163,744,493 shares outstanding as of March\u00a031, 2025; 183,846,725 shares issued and 166,261,112 shares outstanding as of December\u00a031, 2024", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r87", "r547", "r735" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r807" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r806" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r808" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r805" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "NET COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r186", "r188", "r193", "r539", "r558", "r559" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r26", "r27", "r68", "r69", "r269", "r684" ] }, "bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "ConcentrationRiskBusinessRiskPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Business Risk", "label": "Concentration Risk, Business Risk, Policy [Policy Text Block]", "documentation": "Concentration Risk, Business Risk, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r26", "r27", "r68", "r69", "r269", "r590", "r684" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r26", "r27", "r68", "r69", "r269", "r684", "r846" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r684" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration \u200brisk", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r26", "r27", "r68", "r69", "r269" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r25", "r26", "r27", "r28", "r68", "r130", "r684" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r26", "r27", "r68", "r69", "r269", "r684" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r54", "r692" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebate receivable", "label": "Contract with Customer, Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r373", "r374", "r385", "r683" ] }, "us-gaap_CorporateJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateJointVentureMember", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Venture", "label": "Corporate Joint Venture [Member]", "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "COST OF REVENUE", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r97", "r98", "r534" ] }, "us-gaap_CostOfGoodsProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsProductLineMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Service, Product and Service Benchmark", "label": "Cost of Goods and Service, Product and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r845" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of net revenues - drugs", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r99", "r205", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r503", "r700", "r910" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense in cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "bios_CreditAgreementsEnteredInto2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "CreditAgreementsEnteredInto2019Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreements, Entered Into 2019", "label": "Credit Agreements, Entered Into 2019 [Member]", "documentation": "Credit Agreements, Entered Into 2019 [Member]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r316", "r908" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r316", "r908", "r909" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company's Largest Payer", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r114", "r269" ] }, "us-gaap_CustomerListsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerListsMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Referral sources", "label": "Customer Lists [Member]", "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information." } } }, "auth_ref": [ "r53", "r890", "r892", "r893", "r894", "r896", "r897", "r899", "r900" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESS" ], "lang": { "en-us": { "role": { "terseLabel": "INDEBTEDNESS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r119", "r203", "r304", "r305", "r306", "r307", "r308", "r315", "r316", "r326", "r332", "r333", "r334", "r335", "r336", "r337", "r342", "r349", "r350", "r352", "r510" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r15", "r77", "r78", "r132", "r134", "r207", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r707", "r708", "r709", "r710", "r711", "r733", "r859", "r902", "r903", "r904", "r964", "r966" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r15", "r134", "r353" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective rate on term loans at end of period", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r80", "r355", "r510", "r511", "r733" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r207", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r707", "r708", "r709", "r710", "r711", "r733", "r859", "r964", "r966" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r15", "r207", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r707", "r708", "r709", "r710", "r711", "r733", "r859", "r902", "r903", "r904", "r964", "r966" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r15", "r37", "r40", "r73", "r122", "r123", "r207", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r707", "r708", "r709", "r710", "r711", "r733", "r859", "r964", "r966" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r912", "r963", "r964", "r966" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt Issuance Costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r912", "r963", "r964", "r966" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes - net", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r148", "r861" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r431", "r432", "r544" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r442" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r32" ] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization expense", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "negatedTerseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r234", "r246", "r263", "r700", "r701" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivative assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r178", "r179", "r484", "r485", "r495", "r502", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r626", "r627", "r671", "r673", "r674", "r675", "r676", "r677", "r691", "r728", "r731", "r746", "r951", "r952", "r953", "r1006" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r610", "r612", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r633", "r634", "r635", "r636", "r651", "r652", "r653", "r654", "r657", "r658", "r659", "r660", "r671", "r672", "r674", "r676", "r744", "r746", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r60", "r63", "r64", "r129", "r610", "r612", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r633", "r634", "r635", "r636", "r651", "r652", "r653", "r654", "r657", "r658", "r659", "r660", "r671", "r672", "r674", "r676", "r691", "r744", "r746", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r128", "r470", "r478" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r478" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount of derivative", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r947", "r948" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r13", "r55", "r56", "r57", "r58", "r61", "r63", "r65", "r66", "r67", "r478" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, term of contract", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r384", "r713", "r714", "r715", "r716", "r717", "r718", "r719" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r384", "r713", "r714", "r715", "r716", "r717", "r718", "r719" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Revenue Earned by Category of Payer", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED INCENTIVE COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r394", "r398", "r426", "r427", "r428", "r725" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r757" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r789" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r800" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, basic (in dollars per share)", "verboseLabel": "Earnings per common share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r194", "r213", "r214", "r215", "r216", "r217", "r218", "r223", "r225", "r227", "r228", "r229", "r233", "r457", "r462", "r481", "r482", "r540", "r560", "r693" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share, basic", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, diluted (in dollars per share)", "verboseLabel": "Earnings per common share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r194", "r213", "r214", "r215", "r216", "r217", "r218", "r225", "r227", "r228", "r229", "r233", "r457", "r462", "r481", "r482", "r540", "r560", "r693" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share, diluted", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r222", "r230", "r231", "r232" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r434", "r727" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r78" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r755" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r755" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r755" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r839" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r755" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r755" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r755" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r755" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r794" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r835" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r835" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r835" ] }, "bios_EquipmentFurnitureAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "EquipmentFurnitureAndOtherMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, furniture and other", "label": "Equipment, Furniture, And Other [Member]", "documentation": "Equipment, Furniture, And Other [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r158", "r189", "r190", "r191", "r208", "r209", "r210", "r212", "r217", "r219", "r221", "r235", "r276", "r277", "r301", "r372", "r446", "r447", "r454", "r455", "r456", "r458", "r461", "r462", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r514", "r524", "r557", "r584", "r585", "r586", "r601", "r663" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r272", "r273", "r274", "r453", "r841", "r842", "r843", "r943", "r944", "r945", "r946" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution from equity method investments", "verboseLabel": "Distributions received from the investees", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r5", "r7", "r96", "r554" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r272" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity-method investees", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r234", "r251", "r263", "r271", "r848", "r875" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r5", "r70", "r273" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r804" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r762", "r772", "r782", "r814" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r759", "r769", "r779", "r811" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r810" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r340", "r387", "r388", "r389", "r390", "r391", "r392", "r483", "r485", "r486", "r487", "r488", "r494", "r495", "r497", "r531", "r532", "r533", "r708", "r709", "r720", "r721", "r722", "r728", "r731" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r490", "r492", "r493", "r494", "r497", "r498", "r499", "r500", "r501", "r537", "r728", "r732" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Markets for Identical Item (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r340", "r387", "r392", "r485", "r495", "r531", "r720", "r721", "r722", "r728" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r340", "r387", "r392", "r485", "r486", "r495", "r532", "r708", "r709", "r720", "r721", "r722", "r728" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r340", "r387", "r388", "r389", "r390", "r391", "r392", "r485", "r486", "r487", "r488", "r495", "r533", "r708", "r709", "r720", "r721", "r722", "r728", "r731" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r340", "r387", "r388", "r389", "r390", "r391", "r392", "r483", "r485", "r486", "r487", "r488", "r494", "r495", "r497", "r531", "r532", "r533", "r708", "r709", "r720", "r721", "r722", "r728", "r731" ] }, "bios_FiniteLivedCustomerListsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "FiniteLivedCustomerListsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Referral sources, net", "label": "Finite Lived Customer Lists, Net", "documentation": "Finite Lived Customer Lists, Net" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r167", "r278", "r296", "r706" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r289", "r291", "r292", "r293", "r295", "r296", "r298", "r299", "r535", "r536", "r686" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total gross intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r278", "r296", "r536", "r706" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r289", "r296", "r298", "r299", "r300", "r535", "r686", "r706" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r289", "r291", "r292", "r293", "r295", "r296", "r298", "r299", "r686" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r535", "r897" ] }, "bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "FiniteLivedIntangibleAssetsNetExcludingCustomerLists", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists", "documentation": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists" } } }, "auth_ref": [] }, "bios_FirstLienCreditAgreementSecondAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "FirstLienCreditAgreementSecondAmendmentMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Lien Credit Agreement", "label": "First Lien Credit Agreement, Second Amendment [Member]", "documentation": "First Lien Credit Agreement, Second Amendment" } } }, "auth_ref": [] }, "bios_FirstLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "FirstLienTermLoanMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Term Loan", "verboseLabel": "First Lien Term Loan", "label": "First Lien Term Loan [Member]", "documentation": "First Lien Term Loan [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r766", "r776", "r786", "r818" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r766", "r776", "r786", "r818" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r766", "r776", "r786", "r818" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r766", "r776", "r786", "r818" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r766", "r776", "r786", "r818" ] }, "bios_FourVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "FourVendorsMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Four Vendors", "label": "Four Vendors [Member]", "documentation": "Four Vendors" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r799" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill (2)", "periodStartLabel": "Goodwill - net book value, begging of period", "periodEndLabel": "Goodwill - net book value, end of period", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r166", "r279", "r538", "r701", "r705", "r729", "r735", "r879", "r886" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r282", "r705" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r877", "r889" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GovernmentContractsConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentContractsConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Governmental Healthcare Programs", "label": "Government Contracts Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City." } } }, "auth_ref": [ "r114" ] }, "bios_GovernmentCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "GovernmentCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government payers", "label": "Government Customer [Member]", "documentation": "Government Customer [Member]" } } }, "auth_ref": [] }, "bios_GovernmentHealthcareProgramsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "GovernmentHealthcareProgramsMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Healthcare Programs", "label": "Government Healthcare Programs [Member]", "documentation": "Government Healthcare Programs" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "GROSS PROFIT", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r94", "r99", "r141", "r205", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r503", "r695", "r700", "r868", "r870", "r871", "r872", "r873", "r910" ] }, "bios_HCIIncentiveUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "HCIIncentiveUnitsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HC I Incentive Units", "label": "HC I Incentive Units [Member]", "documentation": "HC I Incentive Units [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r13", "r469" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r13" ] }, "bios_IncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "IncomeExpenseAbstract", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (Expense) [Abstract]", "label": "Income (Expense) [Abstract]", "documentation": "Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "INCOME BEFORE INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r95", "r137", "r141", "r541", "r555", "r695", "r700", "r868", "r870", "r871", "r872", "r873" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 }, "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in earnings of joint ventures", "terseLabel": "Equity in earnings of joint ventures", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r7", "r96", "r136", "r234", "r248", "r263", "r271", "r554" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r302", "r309", "r310", "r489", "r491", "r496", "r582", "r583", "r648", "r686", "r730", "r976" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r309", "r310", "r489", "r491", "r496", "r582", "r583", "r648", "r686", "r730", "r976" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r200", "r434", "r435", "r439", "r445", "r727", "r942" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r200", "r434", "r435", "r439", "r445", "r727", "r942" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r206", "r430", "r434", "r436", "r437", "r438", "r440", "r443", "r448", "r450", "r451", "r452", "r597", "r727" ] }, "us-gaap_IncomeTaxExaminationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationLineItems", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination [Line Items]", "label": "Income Tax Examination [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r439" ] }, "us-gaap_IncomeTaxExaminationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationTable", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax, Examination [Table]", "label": "Income Tax, Examination [Table]", "documentation": "Disclosure of information about income tax examination currently in progress or completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior period, and penalty and interest incurred or accrued." } } }, "auth_ref": [ "r941" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAX EXPENSE", "verboseLabel": "Income tax expense", "negatedTerseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r143", "r149", "r220", "r221", "r234", "r249", "r263", "r433", "r434", "r449", "r563", "r727" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r23", "r200", "r444", "r445" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncurrent assets and liabilities", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r766", "r776", "r786", "r810", "r818", "r822", "r830" ] }, "bios_InfusionPumpsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "InfusionPumpsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Infusion pumps", "label": "Infusion Pumps [Member]", "documentation": "Infusion Pumps [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r828" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r758", "r834" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r758", "r834" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r758", "r834" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r14" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense, net", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r245", "r854" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r196", "r198", "r199" ] }, "us-gaap_InterestRateCapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateCapMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap designated as cash flow hedge", "label": "Interest Rate Cap [Member]", "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount." } } }, "auth_ref": [ "r687" ] }, "bios_IntramedPlusIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "IntramedPlusIncMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intramed Plus, Inc", "label": "Intramed Plus, Inc [Member]", "documentation": "Intramed Plus, Inc" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r176", "r690", "r735" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in earnings of joint ventures", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r103", "r104", "r106" ] }, "us-gaap_JuniorLienMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "JuniorLienMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Lien Term Loan", "label": "Junior Lien [Member]", "documentation": "Legal right, after the claims of senior lien holders are satisfied, for a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes second mortgage loans." } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Salaries, benefits, and other employee expense", "label": "Labor and Related Expense", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r853" ] }, "bios_LargestPayerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "LargestPayerMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Largest Payer", "label": "Largest Payer [Member]", "documentation": "Largest Payer" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r117", "r523" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "bios_LegacyHealthSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "LegacyHealthSystemsMember", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy Health Systems", "label": "Legacy Health Systems [Member]", "documentation": "Legacy Health Systems [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r513" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Lease Liabilities, Operating", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r968" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r968" ] }, "bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r513" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undrawn letters of credit issued and outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r15", "r77", "r78", "r79", "r82", "r83", "r84", "r85", "r205", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r464", "r465", "r466", "r503", "r619", "r694", "r753", "r910", "r970", "r971" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r92", "r135", "r550", "r735", "r860", "r876", "r962" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r79", "r162", "r205", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r464", "r465", "r466", "r503", "r735", "r910", "r970", "r971" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r15", "r82", "r83", "r84", "r85", "r205", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r464", "r465", "r466", "r503", "r910", "r970", "r971" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "NONCURRENT LIABILITIES:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LienCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LienCategoryAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lien Category [Axis]", "label": "Lien Category [Axis]", "documentation": "Information by category of lien, for example, but not limited to, senior or junior." } } }, "auth_ref": [] }, "us-gaap_LienCategoryDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LienCategoryDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lien Category [Domain]", "label": "Lien Category [Domain]", "documentation": "Legal claim on the property of another party to secure the payment of a debt or the satisfaction of an obligation by category, for example, but not limited to, senior or junior." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r76", "r81" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Balance", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r15", "r134", "r339", "r354", "r708", "r709", "r733", "r972" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedLabel": "Less: current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r170" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total debt instruments", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r950", "r951", "r952", "r953" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r207", "r344" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r207", "r344" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r207", "r344" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r207", "r344" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r862" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of discount, deferred financing costs and current portion", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r171" ] }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate paid on term loans during period", "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r15", "r902", "r903", "r904" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r34", "r902", "r903", "r904" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r269", "r715", "r737", "r741", "r914", "r973", "r977", "r978", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r802" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r802" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r821" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r829" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r269", "r715", "r737", "r741", "r914", "r973", "r977", "r978", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r803" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r197" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r197" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r109", "r110", "r111" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME", "terseLabel": "Net income", "verboseLabel": "Net income", "netLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r100", "r111", "r138", "r160", "r184", "r187", "r191", "r205", "r211", "r213", "r214", "r215", "r216", "r217", "r220", "r221", "r226", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r457", "r462", "r482", "r503", "r556", "r640", "r661", "r662", "r752", "r910" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r802" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r766", "r776", "r786", "r810", "r818" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r793" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r792" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r810" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r829" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r829" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r105" ] }, "bios_NumberOfInfusionSites": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "NumberOfInfusionSites", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of infusion sites", "label": "Number Of Infusion Sites", "documentation": "Number Of Infusion Sites" } } }, "auth_ref": [] }, "bios_NumberOfInfusionSitesIncludingAdvancesPractitionerCapability": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "NumberOfInfusionSitesIncludingAdvancesPractitionerCapability", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of infusion sites, including advances practitioner capabilities", "label": "Number Of Infusion Sites, Including Advances Practitioner Capability", "documentation": "Number Of Infusion Sites, Including Advances Practitioner Capability" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r701", "r869" ] }, "bios_NumberOfServiceLocations": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "NumberOfServiceLocations", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of service locations", "label": "Number Of Service Locations", "documentation": "Number Of Service Locations" } } }, "auth_ref": [] }, "bios_NumberOfServiceLocationsIncludingAmbulatoryInfusionSuites": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "NumberOfServiceLocationsIncludingAmbulatoryInfusionSuites", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of service locations, including ambulatory infusion suites", "label": "Number Of Service Locations, Including Ambulatory Infusion Suites", "documentation": "Number Of Service Locations, Including Ambulatory Infusion Suites" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense in operating expenses", "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations." } } }, "auth_ref": [ "r14" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING COSTS AND EXPENSES:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "OPERATING INCOME", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r141", "r695", "r868", "r870", "r871", "r872", "r873" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r967" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r516" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r516" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r516" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r517", "r518" ] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePaymentsUse", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating leases", "label": "Operating Lease, Payments, Use", "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r517", "r518" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r515" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease costs", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r857" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate, operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r521", "r734" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term, operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r520", "r734" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r168" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $783 and $(454), respectively", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r181" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in unrealized (loss) gain on cash flows, income tax benefit (expense)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r182" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap designated as cash flow hedge", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r180", "r181", "r467", "r468", "r471" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap designated as cash flow hedge", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r145", "r181", "r183" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "OTHER COMPREHENSIVE (LOSS) INCOME", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r11", "r127", "r185", "r188", "r217" ] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other segment items", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r101", "r562", "r700" ] }, "us-gaap_OtherExpenseDisclosureNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenseDisclosureNonoperatingAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER INCOME (EXPENSE):", "label": "Other Expense, Nonoperating [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r561", "r641", "r678", "r679", "r680" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other amortizable intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r706", "r890", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r83" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r107" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other adjustments", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r802" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r764", "r774", "r784", "r816" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r767", "r777", "r787", "r819" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r767", "r777", "r787", "r819" ] }, "bios_PatientCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "PatientCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patients", "label": "Patient Customer [Member]", "documentation": "Patient Customer [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r791" ] }, "bios_PaymentsForRepurchaseOfCommonStockAndRelatedExciseTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "PaymentsForRepurchaseOfCommonStockAndRelatedExciseTaxes", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of company stock, and related excise taxes", "label": "Payments for Repurchase of Common Stock and Related Excise Taxes", "documentation": "Payments for Repurchase of Common Stock and Related Excise Taxes" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock-based compensation tax withholdings", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r195" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 }, "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Business acquisitions, net of cash acquired", "terseLabel": "Purchase price, net of cash acquired", "totalLabel": "Purchase price, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r20" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r108" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r801" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r801" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r793" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r810" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r803" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r792" ] }, "bios_PerformanceStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "PerformanceStockUnitMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance stock unit awards", "label": "Performance Stock Unit [Member]", "documentation": "Performance Stock Unit" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r794" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r838" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r793" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r744", "r745", "r748", "r749", "r750", "r751", "r1005", "r1007" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r86", "r357" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r86", "r620" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, shares, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r86", "r620", "r638", "r1007", "r1008" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March\u00a031, 2025 and December\u00a031, 2024", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r86", "r546", "r735" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r849" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r844", "r855" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r266", "r534", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r688", "r713", "r736", "r738", "r739", "r742", "r743", "r847", "r906", "r907", "r914", "r973", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r266", "r534", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r688", "r713", "r736", "r738", "r739", "r742", "r743", "r847", "r906", "r907", "r914", "r973", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8", "r523" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r116", "r144", "r146", "r147" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r117", "r164", "r553" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r523" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r523", "r542", "r553", "r735" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r117", "r523" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r791" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r791" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r759", "r769", "r779", "r811" ] }, "bios_ReferralSourcesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "ReferralSourcesMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Referral sources (1)", "label": "Referral Sources [Member]", "documentation": "Referral Sources" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r270", "r393", "r528", "r529", "r545", "r551", "r614", "r615", "r616", "r617", "r618", "r637", "r639", "r670" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r270", "r644", "r645", "r648" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r270", "r393", "r528", "r529", "r545", "r551", "r614", "r615", "r616", "r617", "r618", "r637", "r639", "r670", "r969" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED-PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r525", "r526", "r527", "r529", "r530", "r598", "r599", "r600", "r646", "r647", "r648", "r667", "r669" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of debt principal", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r856" ] }, "bios_ReportableSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "ReportableSegmentMember", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable Segment", "label": "Reportable Segment [Member]", "documentation": "Reportable Segment" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r760", "r770", "r780", "r812" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r761", "r771", "r781", "r813" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r768", "r778", "r788", "r820" ] }, "bios_RestrictedStockAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "RestrictedStockAwardMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards", "label": "Restricted Stock Award [Member]", "documentation": "Restricted Stock Award [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r89", "r124", "r549", "r587", "r589", "r596", "r621", "r735" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r158", "r208", "r209", "r210", "r212", "r217", "r219", "r221", "r276", "r277", "r301", "r446", "r447", "r454", "r455", "r456", "r458", "r461", "r462", "r472", "r474", "r475", "r477", "r480", "r512", "r514", "r584", "r586", "r601", "r1007" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "netLabel": "Management fee income", "terseLabel": "Infusion services net revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r139", "r140", "r234", "r242", "r243", "r257", "r263", "r266", "r268", "r269", "r383", "r384", "r534" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r269", "r845" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bioscrip.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r150", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r386" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "netLabel": "NET REVENUE", "verboseLabel": "Net revenue", "totalLabel": "Total Option Care Health revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r139", "r140", "r192", "r205", "r234", "r242", "r243", "r257", "r263", "r266", "r268", "r269", "r275", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r503", "r541", "r700", "r910" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolver Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in operating lease right-of-use asset and lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r519", "r734" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r829" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r829" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r891", "r896" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r47", "r49", "r459" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Estimated Fair Values of Debt Obligations", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Outstanding Roll Forward", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r60", "r63", "r469" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amount and Location of Derivatives in the Balance Sheet", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r867" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r272", "r273", "r274", "r453", "r841", "r842", "r843", "r943", "r944", "r945", "r946" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Finite-Lived [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r289", "r296", "r298", "r299", "r300", "r535", "r686", "r706" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r705", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Maturities", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8", "r523" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Identifiable Assets and Assumed Liabilities", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r71", "r72", "r644", "r645", "r648" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r35", "r36", "r37", "r38", "r39", "r40", "r120", "r122", "r123", "r124", "r172", "r173", "r174", "r236", "r357", "r358", "r359", "r361", "r364", "r369", "r371", "r592", "r593", "r594", "r595", "r712", "r840", "r858" ] }, "bios_SecondLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "SecondLienTermLoanMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Second Lien Term Loan [Member]", "documentation": "Second Lien Term Loan [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r754" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r756" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r139", "r140", "r141", "r142", "r234", "r238", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r269", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r300", "r311", "r312", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r697", "r700", "r701", "r705", "r740", "r973", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTING" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r142", "r234", "r237", "r238", "r239", "r240", "r241", "r253", "r255", "r256", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r696", "r698", "r699", "r700", "r702", "r703", "r704" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r102" ] }, "us-gaap_SeniorLienMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorLienMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Term Loan", "label": "Senior Lien [Member]", "documentation": "Legal right, before the claims of other creditors, of a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes first mortgage loans." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based incentive compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r395", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r726" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "bios_SharesIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "SharesIssuedDuringPeriodShares", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity award issuances", "label": "Shares Issued During Period, Shares", "documentation": "Shares Issued During Period, Shares" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r112", "r202" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software, purchased and internally developed", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State jurisdiction", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r434" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r139", "r140", "r141", "r142", "r159", "r234", "r238", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r269", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r300", "r303", "r311", "r312", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r697", "r700", "r701", "r705", "r740", "r973", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r87", "r90", "r91", "r158", "r189", "r190", "r191", "r208", "r209", "r210", "r212", "r217", "r219", "r221", "r235", "r276", "r277", "r301", "r372", "r446", "r447", "r454", "r455", "r456", "r458", "r461", "r462", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r514", "r524", "r557", "r584", "r585", "r586", "r601", "r663" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r208", "r209", "r210", "r235", "r514", "r534", "r591", "r602", "r613", "r614", "r615", "r616", "r617", "r618", "r620", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r633", "r634", "r635", "r636", "r637", "r639", "r642", "r643", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r663", "r747" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r208", "r209", "r210", "r235", "r270", "r514", "r534", "r591", "r602", "r613", "r614", "r615", "r616", "r617", "r618", "r620", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r633", "r634", "r635", "r636", "r637", "r639", "r642", "r643", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r663", "r747" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r763", "r773", "r783", "r815" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercise of stock options, vesting of restricted stock, and related tax withholdings", "label": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings", "documentation": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option awards", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r746" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r913" ] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized to be repurchased (in shares)", "label": "Share Repurchase Program, Authorized, Number of Shares", "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r913" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share repurchases", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r12", "r86", "r87", "r124", "r595", "r663", "r681" ] }, "bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20250331", "localname": "StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of company stock, and related tax effects", "label": "Stock Repurchased During Period, Value, Including Related Tax Effects", "documentation": "Stock Repurchased During Period, Value, Including Related Tax Effects" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Equity, beginning balance", "periodEndLabel": "Equity, ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r87", "r90", "r91", "r115", "r622", "r638", "r664", "r665", "r735", "r753", "r860", "r876", "r962", "r1007" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r121", "r204", "r356", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r372", "r479", "r666", "r668", "r682" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Supply Vendors", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r114" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r809" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r801" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r808" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSAdditionalInformationDetails", "http://www.bioscrip.com/role/BUSINESSCOMBINATIONSPreliminaryEstimateoftheAllocationConsiderationTransferredDetails", "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks/names", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r52", "r890", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r828" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r830" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r831" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r832" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r832" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r830" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r830" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r833" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r831" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock acquired, average cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r41" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r41" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r41" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock; 20,631,828 and 17,585,613 shares outstanding, at cost, as of March\u00a031, 2025 and December\u00a031, 2024, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r41", "r42", "r90" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares, acquired (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r12", "r87", "r124" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r12", "r41", "r124" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r827" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Release of valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r441" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r797" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r867" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "totalLabel": "Weighted average number of common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r224", "r229" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r223", "r229" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r795" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r840": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r841": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 83 0001014739-25-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001014739-25-000022-xbrl.zip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ʊ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bios-20250331_htm.xml IDEA: XBRL DOCUMENT 0001014739 2025-01-01 2025-03-31 0001014739 2025-04-25 0001014739 2025-03-31 0001014739 2024-12-31 0001014739 2024-01-01 2024-03-31 0001014739 2023-12-31 0001014739 2024-03-31 0001014739 us-gaap:PreferredStockMember 2023-12-31 0001014739 us-gaap:CommonStockMember 2023-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2023-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001014739 us-gaap:RetainedEarningsMember 2023-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001014739 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001014739 us-gaap:PreferredStockMember 2024-03-31 0001014739 us-gaap:CommonStockMember 2024-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2024-03-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001014739 us-gaap:RetainedEarningsMember 2024-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001014739 us-gaap:PreferredStockMember 2024-12-31 0001014739 us-gaap:CommonStockMember 2024-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2024-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001014739 us-gaap:RetainedEarningsMember 2024-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001014739 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001014739 us-gaap:PreferredStockMember 2025-03-31 0001014739 us-gaap:CommonStockMember 2025-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2025-03-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001014739 us-gaap:RetainedEarningsMember 2025-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001014739 bios:LegacyHealthSystemsMember 2025-03-31 0001014739 us-gaap:CorporateJointVentureMember 2024-01-01 2024-03-31 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2024-01-01 2024-03-31 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2025-01-01 2025-03-31 0001014739 bios:GovernmentHealthcareProgramsMember bios:AccountsReceivableBenchmarkMember us-gaap:GovernmentContractsConcentrationRiskMember 2025-01-01 2025-03-31 0001014739 bios:GovernmentHealthcareProgramsMember bios:AccountsReceivableBenchmarkMember us-gaap:GovernmentContractsConcentrationRiskMember 2024-01-01 2024-12-31 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2025-01-01 2025-03-31 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2024-01-01 2024-03-31 0001014739 bios:IntramedPlusIncMember 2025-01-24 0001014739 bios:IntramedPlusIncMember 2025-01-24 2025-01-24 0001014739 bios:IntramedPlusIncMember bios:ReferralSourcesMember 2025-01-24 0001014739 bios:IntramedPlusIncMember us-gaap:TrademarksAndTradeNamesMember 2025-01-24 0001014739 bios:IntramedPlusIncMember bios:ReferralSourcesMember 2025-01-24 2025-01-24 0001014739 bios:IntramedPlusIncMember us-gaap:TrademarksAndTradeNamesMember 2025-01-24 2025-01-24 0001014739 bios:CommercialCustomerMember 2025-01-01 2025-03-31 0001014739 bios:CommercialCustomerMember 2024-01-01 2024-03-31 0001014739 bios:GovernmentCustomerMember 2025-01-01 2025-03-31 0001014739 bios:GovernmentCustomerMember 2024-01-01 2024-03-31 0001014739 bios:PatientCustomerMember 2025-01-01 2025-03-31 0001014739 bios:PatientCustomerMember 2024-01-01 2024-03-31 0001014739 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-03-31 0001014739 us-gaap:StateAndLocalJurisdictionMember 2025-03-31 0001014739 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001014739 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0001014739 bios:RestrictedStockAwardMember 2025-01-01 2025-03-31 0001014739 bios:RestrictedStockAwardMember 2024-01-01 2024-03-31 0001014739 bios:PerformanceStockUnitMember 2025-01-01 2025-03-31 0001014739 bios:PerformanceStockUnitMember 2024-01-01 2024-03-31 0001014739 bios:InfusionPumpsMember 2025-03-31 0001014739 bios:InfusionPumpsMember 2024-12-31 0001014739 bios:EquipmentFurnitureAndOtherMember 2025-03-31 0001014739 bios:EquipmentFurnitureAndOtherMember 2024-12-31 0001014739 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001014739 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001014739 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-03-31 0001014739 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-12-31 0001014739 us-gaap:AssetUnderConstructionMember 2025-03-31 0001014739 us-gaap:AssetUnderConstructionMember 2024-12-31 0001014739 us-gaap:CostOfSalesMember 2025-01-01 2025-03-31 0001014739 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0001014739 us-gaap:OperatingExpenseMember 2025-01-01 2025-03-31 0001014739 us-gaap:OperatingExpenseMember 2024-01-01 2024-03-31 0001014739 us-gaap:CustomerListsMember 2025-03-31 0001014739 us-gaap:CustomerListsMember 2024-12-31 0001014739 us-gaap:TrademarksAndTradeNamesMember 2025-03-31 0001014739 us-gaap:TrademarksAndTradeNamesMember 2024-12-31 0001014739 us-gaap:OtherIntangibleAssetsMember 2025-03-31 0001014739 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember us-gaap:SeniorNotesMember 2025-03-31 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2025-03-31 0001014739 bios:SecondLienTermLoanMember us-gaap:SeniorNotesMember 2025-03-31 0001014739 us-gaap:RevolvingCreditFacilityMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:SecondLienTermLoanMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2025-03-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2025-01-01 2025-03-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-01-01 2024-03-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2025-03-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2024-01-01 2024-03-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2025-01-01 2025-03-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2025-03-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:FirstLienCreditAgreementSecondAmendmentMember us-gaap:SeniorNotesMember 2025-03-31 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:SeniorNotesMember 2025-03-31 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2025-03-31 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember 2025-03-31 0001014739 us-gaap:SeniorNotesMember 2025-03-31 0001014739 us-gaap:FairValueInputsLevel1Member us-gaap:SeniorNotesMember 2025-03-31 0001014739 us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2025-03-31 0001014739 us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember 2025-03-31 0001014739 us-gaap:FairValueInputsLevel1Member 2025-03-31 0001014739 us-gaap:FairValueInputsLevel2Member 2025-03-31 0001014739 us-gaap:FairValueInputsLevel3Member 2025-03-31 0001014739 bios:FirstLienTermLoanMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2021-10-31 0001014739 bios:FirstLienTermLoanMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2021-10-01 2021-10-31 0001014739 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-31 0001014739 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0001014739 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-03-31 0001014739 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0001014739 us-gaap:InterestRateCapMember 2025-01-01 2025-03-31 0001014739 us-gaap:InterestRateCapMember 2024-01-01 2024-03-31 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2025-01-01 2025-03-31 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0001014739 bios:A2018PlanMember 2021-05-31 0001014739 bios:A2018PlanMember 2024-05-01 2024-05-31 0001014739 2024-05-31 0001014739 bios:HCIIncentiveUnitsMember bios:A2018PlanMember 2025-01-01 2025-03-31 0001014739 bios:HCIIncentiveUnitsMember bios:A2018PlanMember 2024-01-01 2024-03-31 0001014739 us-gaap:CommonStockMember 2023-12-06 0001014739 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001014739 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001014739 us-gaap:CorporateJointVentureMember 2025-01-01 2025-03-31 0001014739 us-gaap:CorporateJointVentureMember 2025-03-31 0001014739 us-gaap:CorporateJointVentureMember 2024-12-31 0001014739 bios:ReportableSegmentMember 2025-01-01 2025-03-31 0001014739 bios:ReportableSegmentMember 2024-01-01 2024-03-31 shares iso4217:USD iso4217:USD shares bios:pharmacy bios:suite bios:segment pure 0001014739 --12-31 2025 Q1 false 10-Q true 2025-03-31 false 001-11993 OPTION CARE HEALTH, INC. DE 05-0489664 3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 312 940-2443 Common Stock, $0.0001 par value per share OPCH NASDAQ Yes Yes Large Accelerated Filer false false false 163747250 171372000 412565000 476649000 409733000 369034000 388131000 82320000 112198000 1099375000 1322627000 131264000 127367000 90950000 86528000 24427000 16993000 312586000 284017000 1605930000 1540246000 43981000 43965000 2209138000 2099116000 3308513000 3421743000 528848000 610779000 49664000 63028000 106177000 77783000 22463000 22044000 6512000 6512000 713664000 780146000 1104160000 1104641000 89825000 84776000 48946000 47576000 1084000 366000 1244015000 1237359000 1957679000 2017505000 0.0001 0.0001 12500000 12500000 0 0 0 0 0.0001 0.0001 250000000 250000000 184376321 163744493 183846725 166261112 18000 18000 20631828 17585613 608711000 507598000 1234800000 1231435000 716078000 669336000 8649000 11047000 1350834000 1404238000 3308513000 3421743000 1332972000 1146052000 1069920000 907552000 263052000 238500000 168118000 154742000 15746000 14728000 183864000 169470000 79188000 69030000 13231000 13202000 1729000 1125000 -4130000 2000 -15632000 -12075000 63556000 56955000 16814000 12164000 46742000 44791000 -783000 454000 -2398000 1551000 -2398000 1551000 44344000 46342000 0.28 0.26 0.28 0.26 165460000 173928000 166804000 175624000 46742000 44791000 16373000 15305000 9002000 7663000 1370000 2964000 1147000 1132000 1729000 1125000 8801000 9605000 0 750000 -949000 108000 56788000 195992000 -21790000 -32056000 -28444000 -4878000 -88101000 59223000 -14458000 -49884000 27503000 6811000 7956000 6651000 -1595000 418000 -7214000 -68784000 9371000 5820000 117322000 0 -126693000 -5820000 7385000 8182000 100222000 40050000 1628000 1500000 1949000 0 -107286000 -49732000 -241193000 -124336000 412565000 343849000 171372000 219513000 10763000 12173000 833000 2000 7548000 7085000 0 18000 -255107000 1204270000 457513000 14978000 1421672000 8182000 8182000 9605000 9605000 40289000 40289000 44791000 44791000 1551000 1551000 0 18000 -295396000 1205693000 502304000 16529000 1429148000 0 18000 -507598000 1231435000 669336000 11047000 1404238000 5436000 5436000 8801000 8801000 101113000 101113000 46742000 46742000 -2398000 -2398000 0 18000 -608711000 1234800000 716078000 8649000 1350834000 NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Organization and Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 91 full service pharmacies, including 77 with ambulatory infusion suites. Additionally, the Company has 99 stand-alone ambulatory infusion suites, including 16 with advanced practitioner capabilities. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company’s stock is listed on the Nasdaq Global Select Market as of March 31, 2025.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2024 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company’s equity-method investments.</span></div> 91 77 99 16 1 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2024 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div> 0.50 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2025, cash equivalents consisted of money market funds.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $33.9 million and $54.4 million as of March 31, 2025 and December 31, 2024, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2025 and December 31, 2024, the balance of the investments was $26.2 million and $24.5 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.7 million and $1.1 million for the three months ended March 31, 2025 and 2024, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% and 14% for the three months ended March 31, 2025 and 2024, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, approximately 12% of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and December 31, 2024, approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 11%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, approximately 66% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2025, cash equivalents consisted of money market funds.</span></div> 33900000 54400000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2025 and December 31, 2024, the balance of the investments was $26.2 million and $24.5 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.7 million and $1.1 million for the three months ended March 31, 2025 and 2024, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div> 26200000 24500000 1700000 1100000 800000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% and 14% for the three months ended March 31, 2025 and 2024, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, approximately 12% of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and December 31, 2024, approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 11%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025 and 2024, approximately 66% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results.</span></div> 0.15 0.14 0.12 0.12 0.11 0.11 0.66 0.66 BUSINESS COMBINATIONS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intramed Plus, Inc. —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 24, 2025, pursuant to the securities purchase agreement dated November 27, 2024, the Company completed the acquisition of 100% of the equity interests in Intramed Plus, Inc. (“Intramed Plus”) for a purchase price, net of cash acquired, of $117.3 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the purchase price of Intramed Plus was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the total purchase price being allocated to the assets and liabilities acquired based on the relative fair value of each asset and liability. The following is a preliminary estimate of the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2025, which remains open for accounts receivable, accounts payable and intangible assets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value identifiable assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,290 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: cash acquired </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase price, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,322 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Referral sources and trademarks/names have been assigned a useful life of 15 years.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.</span></div> 1 117300000 The following is a preliminary estimate of the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2025, which remains open for accounts receivable, accounts payable and intangible assets (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value identifiable assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,290 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: cash acquired </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase price, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,322 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Referral sources and trademarks/names have been assigned a useful life of 15 years.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.</span></div> 10128000 36800000 8300000 2693000 4831000 11114000 51638000 65684000 2968000 120290000 2968000 117322000 P15Y P15Y REVENUE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2025 and 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,972 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2025 and 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,972 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1144932000 988043000 160518000 138310000 27522000 19699000 1332972000 1146052000 INCOME TAXES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, the Company recorded tax expense of $16.8 million and $12.2 million, respectively, which represents an effective tax rate of 26.5% and 21.4%, respectively. The variance in the Company’s effective tax rate of 26.5% for the three months ended March 31, 2025, compared to the federal statutory rate of 21.0%, is primarily attributable to the difference between federal and state tax rates, and various non-deductible expenses. The variance in the Company’s effective tax rate of 21.4% for the three months ended March 31, 2024, compared to the federal statutory rate of 21.0%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the three months ended March 31, 2024, the Company released $2.2 million of state valuation allowance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance of $3.3 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s tax expense of $16.8 million and $12.2 million for the three months ended March 31, 2025 and 2024, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.</span></div>The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (“Code”) Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses 16800000 12200000 0.265 0.214 0.265 0.214 -2200000 3300000 16800000 12200000 EARNINGS PER SHARE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March 31, 2025 and 2024 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880,815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,624 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880,815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 702287 880815 604589 279144 171854 149561 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,624 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 46742000 44791000 165460000 173928000 0.28 0.26 46742000 44791000 165460000 173928000 1344000 1696000 166804000 175624000 0.28 0.26 LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, the Company incurred operating lease expenses of $8.2 million and $7.9 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the weighted-average remaining lease term was 6.6 years and 6.5 years, respectively, and the weighted-average discount rate was 6.77% and 6.56%, respectively.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flows o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.8 million and $11.3 million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of March 31, 2025, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div> LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, the Company incurred operating lease expenses of $8.2 million and $7.9 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the weighted-average remaining lease term was 6.6 years and 6.5 years, respectively, and the weighted-average discount rate was 6.77% and 6.56%, respectively.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flows o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.8 million and $11.3 million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of March 31, 2025, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div> 8200000 7900000 P6Y7M6D P6Y6M 0.0677 0.0656 <div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21946000 27537000 22446000 15840000 11233000 43576000 142578000 30290000 112288000 10800000 11300000 PROPERTY AND EQUIPMENT<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of March 31, 2025 and December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,414 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,911 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2025 and 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,276 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of March 31, 2025 and December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,414 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,911 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2025 and 2024 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,276 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 38623000 37659000 21222000 24055000 117828000 116675000 48365000 46532000 25376000 22990000 251414000 247911000 120150000 120544000 131264000 127367000 627000 576000 6649000 6120000 7276000 6696000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill consist of the following for the three months ended March 31, 2025 (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605,930 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2025 and December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262,596)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,010 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $9.1 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill consist of the following for the three months ended March 31, 2025 (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605,930 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1540246000 65684000 1605930000 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2025 and December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262,596)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,010 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 551188000 514388000 47436000 39136000 985000 985000 599609000 554509000 238602000 230371000 23416000 22599000 578000 529000 262596000 253499000 337013000 301010000 9100000 8600000 INDEBTEDNESS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of March 31, 2025 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129,988 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,122)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104,160 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131,617 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104,641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the First Lien Term Loan was 6.57% and 6.82% as of March 31, 2025 and December 31, 2024, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 6.58% and 8.20% for the three months ended March 31, 2025 and 2024, respectively. The First Lien Term Loan matures on October 27, 2028.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Senior Notes was 4.375% as of March 31, 2025 and December 31, 2024. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three months ended March 31, 2025 and 2024. The Senior Notes mature on October 31, 2029.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129,988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2025 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110,672 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,095,313 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of March 31, 2025 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129,988 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,122)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104,160 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131,617 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104,641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 0 629988000 5194000 7087000 617707000 500000000 0 7035000 492965000 1129988000 5194000 14122000 1110672000 6512000 1104160000 0 0 0 0 631617000 5537000 7555000 618525000 500000000 0 7372000 492628000 1131617000 5537000 14927000 1111153000 6512000 1104641000 0.0657 0.0682 0.0658 0.0820 0.04375 0.04375 0.04375 0.04375 4100000 395900000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129,988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4884000 6512000 6512000 612080000 500000000 1129988000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2025 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110,672 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,095,313 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 617707000 0 631563000 0 492965000 0 463750000 0 1110672000 0 1095313000 0 DERIVATIVE INSTRUMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a five-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,533 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,714 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the hedging instrument is recognized in net income through interest expense.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,181)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 300000000 P5Y <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,533 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,714 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7515000 8034000 4018000 6680000 11533000 14714000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,181)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -3181000 2005000 2191000 2980000 FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value at March 31, 2025 and December 31, 2024.</span></div> FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value at March 31, 2025 and December 31, 2024.</span></div> COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</span></div> STOCK-BASED INCENTIVE COMPENSATION<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by stockholders on May 3, 2018 and amended and restated on May 19, 2021 and May 15, 2024, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. As of May 2021, a total of 9,101,734 shares of common stock were authorized for issuance under the 2018 Plan. In May 2024, an additional 4,000,000 shares were authorized for issuance under the 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March 31, 2025 and 2024. During the three months ended March 31, 2025 and 2024, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $8.8 million and $9.6 million, respectively.</span></div> 9101734 4000000 13101734 8800000 9600000 STOCKHOLDERS’ EQUITY<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— As of March 31, 2025 and December 31, 2024, the Company has warrants outstanding which entitle holders to purchase an immaterial number of shares of common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company’s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, the Company purchased 3,046,215 and 1,251,739 shares of common stock for an average share price of $32.83 and $31.96, totaling $100.0 million and $40.0 million, respectively. All repurchased shares became treasury stock. As of March 31, 2025, the Company is authorized to repurchase up to a remaining $400.0 million of common stock of the Company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The following table shows the Company’s changes in shares of common stock for the three months ended March 31, 2025 and 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance March 31,</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 500000000.0 3046215 1251739 32.83 31.96 100000000.0 40000000.0 400000000.0 The following table shows the Company’s changes in shares of common stock for the three months ended March 31, 2025 and 2024 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance March 31,</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 166261000 174576000 529000 492000 3046000 1252000 163744000 173816000 RELATED-PARTY TRANSACTIONS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Equity-Method Investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.8 million and $1.5 million for the three months ended March 31, 2025 and 2024, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March 31, 2025, the Company did not receive any distributions from the investees. During the three months ended March 31, 2024, the Company received distributions from the investees of $0.8 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had amounts due to its joint ventures of $2.5 million and $1.4 million as of March 31, 2025 and December 31, 2024, respectively. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.</span></div> 1800000 1500000 800000 2500000 1400000 SEGMENT REPORTING<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and has revised prior year disclosures to conform with the current year presentation. The Company operates as a single reportable segment, infusion services. Infusion services derives revenue through the clinical management of infusion therapy, nursing support and care coordination in order to provide solutions to complex patient conditions in the home or other nonhospital settings. The Company’s infusion services segment activities are managed on a consolidated basis and therapies are distributed and administered in a similar manner.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments have been identified based on the financial information utilized by the Company’s Chief Executive Officer, the chief operating decision maker (“CODM”). The CODM uses net income as a measure of profitability to assess segment performance and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects results of operations of the Company’s reportable segment (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion services net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,311,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Option Care Health revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Expense) Income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of net revenues - drugs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(933,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(777,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries, benefits, and other employee expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment items (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99,278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,742 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents business activities related to other miscellaneous revenue streams.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects results of operations of the Company’s reportable segment (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion services net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,311,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Option Care Health revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Expense) Income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of net revenues - drugs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(933,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(777,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries, benefits, and other employee expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment items (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99,278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,742 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents business activities related to other miscellaneous revenue streams.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.</span></div> 1311181000 1125662000 21791000 20390000 1332972000 1146052000 933068000 777260000 205692000 191815000 99278000 93219000 15746000 14728000 13231000 13202000 1729000 1125000 -4130000 2000 16814000 12164000 46742000 44791000 false false false false